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Abstract
Tranexamic acid to reduce head injury death in people with
traumatic brain injury: the CRASH-3 international RCT
Ian Roberts ,1* Haleema Shakur-Still ,1 Amy Aeron-Thomas ,2
Danielle Beaumont ,1 Antonio Belli ,3 Amy Brenner ,1
Madeleine Cargill ,1 Rizwana Chaudhri ,4 Nicolas Douglas ,5
Lauren Frimley ,1 Catherine Gilliam ,1 Amber Geer ,1 Zahra Jamal ,1
Rashid Jooma ,6 Raoul Mansukhani ,1 Alec Miners ,5 Jason Pott ,7
Danielle Prowse ,1 Temitayo Shokunbi 8 and Jack Williams 5
1Clinical
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3National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre,
Queen Elizabeth Hospital, Birmingham, UK
4Department of Obstetrics and Gynaecology, Rawalpindi Medical University, Rawalpinidi, Pakistan
5Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine,
London, UK
6Department of Surgery, The Aga Khan University Medical College, Karachi, Pakistan
7Emergency Department, Barts Health NHS Trust, The Royal London Hospital, London, UK
8Department of Anatomy and Surgery, University of Ibadan, Ibadan, Nigeria
2RoadPeace,

*Corresponding author Ian.Roberts@lshtm.ac.uk
Background: Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial
bleeding is common after traumatic brain injury and can cause brain herniation and death. We assessed
the effects of tranexamic acid in traumatic brain injury patients.
Objective: To assess the effects of tranexamic acid on death, disability and vascular occlusive events in
traumatic brain injury patients. We also assessed cost-effectiveness.
Design: Randomised trial and economic evaluation. Patients were assigned by selecting a numbered
treatment pack from a box containing eight packs that were identical apart from the pack number.
Patients, caregivers and those assessing outcomes were masked to allocation. All analyses were by
intention to treat. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a
UK NHS perspective using the trial results and a Markov model.
Setting: 175 hospitals in 29 countries.
Participants: Adults with traumatic brain injury within 3 hours of injury with a Glasgow Coma Scale
score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no major extracranial
bleeding, were eligible.
Intervention: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or
matching placebo.
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ABSTRACT

Main outcome measures: Head injury death in hospital within 28 days of injury in patients treated within
3 hours of injury. Secondary outcomes were early head injury deaths, all-cause and cause-specific mortality,
disability, vascular occlusive events, seizures, complications and adverse events.
Results: Among patients treated within 3 hours of injury (n = 9127), the risk of head injury death was 18.5%
in the tranexamic acid group versus 19.8% in the placebo group (855/4613 vs. 892/4514; risk ratio 0.94, 95%
confidence interval 0.86 to 1.02). In a prespecified analysis excluding patients with a Glasgow Coma Scale
score of 3 or bilateral unreactive pupils at baseline, the results were 12.5% in the tranexamic acid group
versus 14.0% in the placebo group (485/3880 vs. 525/3757; risk ratio 0.89, 95% confidence interval 0.80
to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to
moderate head injury (166/2846 vs. 207/2769; risk ratio 0.78, 95% confidence interval 0.64 to 0.95), but in
those with severe head injury (689/1739 vs. 685/1710; risk ratio 0.99, 95% confidence interval 0.91 to 1.07)
there was no apparent reduction (p-value for heterogeneity = 0.030). Early treatment was more effective in
mild and moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in cases of
severe head injury (p = 0.73). The risk of disability, vascular occlusive events and seizures was similar in both
groups. Tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury (base case of
£4288 per quality-adjusted life-year gained).
Conclusion: Early tranexamic acid treatment reduces head injury deaths. Treatment is cost-effective
for patients with mild or moderate traumatic brain injury, or those with both pupils reactive.
Future work: Further trials should examine early tranexamic acid treatment in mild head injury.
Research on alternative routes of administration is needed.
Limitations: Time to treatment may have been underestimated.
Trial registration: Current Controlled Trials ISRCTN15088122, ClinicalTrials.gov NCT01402882,
EudraCT 2011-003669-14, Pan African Clinical Trial Registry PACTR20121000441277.
Funding: The project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26.
See the NIHR Journals Library website for further project information. In addition, funding was provided
by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for
International Development and the Wellcome Trust). This project was funded by the NIHR Global Health
Trials programme.
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Plain English summary

T

raumatic brain injury is a leading cause of death and disability worldwide, with over 60 million new
cases each year.

When the head is injured there is often bleeding inside the brain, which can continue for some time
and worsen after hospital admission. This bleeding increases pressure inside the skull, causing further
damage to the brain, which can be fatal or result in serious disability.
Tranexamic acid is a cheap drug that reduces bleeding in other conditions. A large trial of accident
victims (other than those with head injury) found that it reduced the chances of bleeding to death.
We wanted to find out if tranexamic acid would also reduce deaths among patients with head injuries.
We studied just under 13,000 patients with traumatic brain injury who did not have other major
injuries to their bodies from 175 hospitals across 29 countries. Patients were assigned at random to
receive either tranexamic acid or a dummy medicine called a placebo. Neither the clinical team nor the
patient knew which medicine the patient received. All patients received the usual treatments given to
head-injured patients.
Outcomes from 9127 participants were analysed. Among patients treated early, within 3 hours, the
rate of head injury death was 18.5% (855/4613) in the tranexamic acid group and 19.8% (892/4514) in
the placebo group. We found no evidence of an effect of tranexamic acid overall. However, in patients
with mild or moderate traumatic brain injury, there was a 20% reduction in deaths. There were no
side effects and no increase in disability in survivors when the drug was used. The economic analysis
shows that tranexamic acid represents value for money for patients with mild or moderate traumatic
brain injury.
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Scientific summary
Background
Traumatic brain injury is the leading cause of injury-related death and disability globally. Each year,
worldwide, there are over 60 million new cases of traumatic brain injury. Tranexamic acid reduces deaths
due to blood loss in trauma patients with significant extracranial bleeding. Intracranial bleeding is common
after traumatic brain injury and can cause brain herniation and death. Tranexamic acid may improve
outcomes in patients with intracranial bleeding by reducing the expansion of intracranial haemorrhages.
This is supported by data from a meta-analysis of randomised controlled trials of tranexamic acid in
traumatic brain injury, which showed a significant reduction in haemorrhage growth and mortality with
tranexamic acid. An effective, widely practicable and affordable treatment for traumatic brain injury could
save many thousands of lives and substantially reduce the burden of disability.

Objective
We assessed the effects and cost-effectiveness of tranexamic acid in traumatic brain injury patients on
death, disability, vascular occlusive events, seizures, complications and adverse events.

Methods
The CRASH-3 (Clinical Randomisation of an Antifibrinolytic in Significant Head Injury-3) trial was an
international, multicentre, randomised, placebo-controlled trial conducted in 175 hospitals in 29 countries.
Adults with traumatic brain injury (n = 12,737) who were within 3 hours of injury and had a Glasgow
Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no
significant extracranial bleeding, were eligible. The time window for eligibility was originally within
8 hours of injury. However, in September 2016, in response to evidence external to the trial indicating
that tranexamic acid is unlikely to be effective when initiated beyond 3 hours of injury, the Trial Steering
Committee amended the protocol to limit recruitment to within 3 hours of injury.
Patients were randomly allocated to receive tranexamic acid (loading dose of 1 g over 10 minutes and
then infusion of 1 g over 8 hours) or matched placebo. Patients were assigned to their treatment group
by selecting a numbered treatment pack from a box containing eight packs that were identical apart
from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation.
The primary outcome was head injury death in hospital within 28 days of injury in patients randomised
within 3 hours of injury. Secondary outcomes were early head injury death (within 24 and 48 hours after
injury), all-cause and cause-specific mortality, disability, vascular occlusive events (myocardial infarction,
stroke, deep-vein thrombosis, pulmonary embolism), seizures, complications, neurosurgery, days in an
intensive care unit and adverse events within 28 days of randomisation. A diagnosis of deep-vein thrombosis
or pulmonary embolism was recorded only if there was a positive result on imaging (e.g. ultrasound) or at
post-mortem examination. We assessed the cost-effectiveness of tranexamic acid versus no treatment
from a UK NHS perspective using a Markov model and data directly from the CRASH-3 trial. We estimated
incremental cost-effectiveness ratios by dividing the incremental costs (in Great British pounds) by the
incremental quality-adjusted life-years. We compared incremental cost-effectiveness ratios to the UK
cost-effectiveness threshold of £20,000 per quality-adjusted life-year.
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To minimise the risk of missing data, we developed simple data collection tools and kept data collection
to a minimum. For the primary analysis, we conducted a complete-case analysis with no imputation
for missing data. All analyses were by intention to treat. A subgroup analysis was conducted of the
effect of tranexamic acid according to the time interval between injury and tranexamic acid treatment
(≤ 1, > 1 to ≤ 3, > 3 hours). The effects of tranexamic acid on the primary outcome were also stratified
by severity of head injury, blood pressure and age.

Results
Patients were allocated to tranexamic acid (n = 6406) or to placebo (n = 6331); 6359 and 6280
patients, respectively, were analysed. A total of 9202 patients were enrolled within 3 hours of injury,
of whom 9127 had outcome data available for analysis (tranexamic acid group, n = 4613; placebo
group, n = 4514).

Primary outcome
Among patients treated early, the risk of head injury death was 18.5% in the tranexamic acid group
versus 19.8% in the placebo group (855 vs. 892 events, risk ratio 0.94, 95% confidence interval 0.86 to
1.02). In the prespecified sensitivity analysis that excluded patients with a Glasgow Coma Scale score
of 3 or with bilateral unreactive pupils at baseline (tranexamic acid group, n = 3880; placebo group,
n = 3757), the risk of head injury death was 12.5% in the tranexamic acid group and 14.0% in the
placebo group (485 vs. 525 events; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a
reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head
injury [5.8% (166/2846) vs. 7.5% (207/2769); risk ratio 0.78, 95% confidence interval 0.64 to 0.95], but
in those with severe head injury [39.6% (689/1739) vs. 40.1% (685/1710); risk ratio 0.99, 95% confidence
interval 0.91 to 1.07] there was no clear evidence of a reduction (p-value for heterogeneity = 0.030).
Early treatment was more effective in mild and moderate head injury (p = 0.005), but there was no obvious
impact of time to treatment in severe head injury (p = 0.73).

Secondary outcome
The risk of disability, vascular occlusive events and seizures was similar in both groups. There was no
apparent benefit or harm among those randomised beyond 3 hours of injury.
The cost-effectiveness analysis showed that tranexamic acid is highly cost-effective for mild and moderate
traumatic brain injury with an incremental cost-effectiveness ratio of £4288 per quality-adjusted life-year
gained, and was also cost-effective for patients with both pupils reactive, with an incremental costeffectiveness ratio of £6097 per quality-adjusted life-year gained. The results were highly robust in
probabilistic sensitivity analyses, with treatment 99% likely to be cost-effective at the UK costeffectiveness threshold of £20,000 per quality-adjusted life-year, in both of these populations.

Conclusion
Tranexamic acid is safe in traumatic brain injury patients, and treatment within 3 hours of injury
reduces head injury deaths. Patients should be treated as soon as possible after injury. Treatment is
highly likely to be cost-effective for those with mild or moderate traumatic brain injury, or those with
both pupils reactive.
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Implications for practice
On the basis of the CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage-2)
trial results, tranexamic acid was included in guidelines for the pre-hospital care of patients with trauma.
However, patients with isolated traumatic brain injury were specifically excluded. The CRASH-3 trial
provides evidence that tranexamic acid is safe for use in patients with traumatic brain injury and that
treatment within 3 hours of injury reduces head injury-related deaths. In the light of this evidence, the
exclusion of patients with isolated traumatic brain injury from tranexamic acid treatment guidelines seems
unnecessary. This is supported by economic evidence that shows that the treatment of patients with mild
or moderate traumatic brain injury, or with both pupils reactive, is highly cost-effective.

Recommendations for future research
Based on the CRASH-3 trial results, patients with traumatic brain injury within 3 hours of injury, who
have a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan
are likely to be treated with tranexamic acid, either at the scene of the injury or after arrival in hospital.
However, most patients with mild traumatic brain injury will not receive pre-hospital tranexamic acid
and, by the time they have been assessed in hospital, for many patients it will be either too late to give
tranexamic acid or too late to experience the full benefits of early treatment. Even mild traumatic brain
injury can have important consequences (death and disability), especially in older adults. Further
research into the effects of the early (including pre-hospital) use of tranexamic acid in older adults with
mild traumatic brain injury is needed.
Immediate tranexamic acid treatment improves survival, but the treatment benefit decreases by about
10% for every 15 minutes of treatment delay until 3 hours, after which there is no benefit. One of the
main obstacles to further reducing treatment delay is the need for an intravenous injection. If tranexamic
acid could be given by intramuscular injection, this might reduce the time to tranexamic acid treatment.
To determine whether or not intramuscular tranexamic acid has the potential to improve the care of
trauma patients, research is required to understand the pharmacokinetics of tranexamic acid following
intramuscular use. If we find that intramuscular tranexamic acid is well absorbed, with therapeutic
tranexamic acid levels achieved in a timely manner, intramuscular tranexamic acid would provide a rapid
alternative to intravenous injection use when immediate intravenous injection administration is not possible.

Trial registration
This trial is registered as ISRCTN15088122 (19 July 2011), ClinicalTrials.gov number NCT01402882
(26 July 2011) and EudraCT 2011-003669-14 (12 June 2012) and in the Pan African Clinical Trial
Registry as PACTR20121000441277 (30 October 2012).

Funding
The project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26.
See the NIHR Journals Library website for further project information. In addition funding was
provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council,
Department for International Development and the Wellcome Trust). This project was funded by the
NIHR Global Health Trials programme.
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Chapter 1 Introduction

E

ach year, worldwide, there are over 60 million new cases of traumatic brain injury (TBI).1 Low- and
middle-income countries (LMIC) bear a disproportionate burden of morbidity and mortality due to
TBI compared with high-income countries. In LMIC, TBI is most commonly the result of road traffic
accidents, whereas in high-income countries the mechanism of injury for TBI appears to be shifting
from road traffic accidents to falls by the elderly.1 With rapid urbanisation in LMIC and the resulting
increase in motorisation, cases of TBI are expected to rise.2
The impact of TBI can be devastating for individuals and their families. Survivors of TBI may experience
long-term physical, emotional and cognitive dysfunction. This, in turn, has considerable financial
consequences through health and social costs and wider economic impacts due to reduced productivity.

Traumatic brain injury mechanism
Traumatic brain injury is an acute injury to the brain from an external mechanical force that temporarily
or permanently impairs brain function. TBI is often classified as mild, moderate or severe according to the
patient’s level of consciousness. This is assessed clinically using the Glasgow Coma Scale (GCS).3
Bleeding within the skull (known as intracranial haemorrhage) is common after TBI and is associated
with increased mortality and morbidity.4 Although bleeding can start from the moment of impact, it
often continues for several hours after injury.5,6 In the CRASH-1 (Corticosteroid Randomisation After
Significant Head Injury) trial,7 which included 10,008 TBI patients, 73% of patients with moderate or
severe TBI had intracranial haemorrhage on computerised tomography (CT) scan. Bleeding progressed
in 84% of these patients with confirmed intracranial haemorrhage and moderate or severe TBI.

Management of traumatic brain injury
The skull is a rigid compartment containing three components: brain, blood and cerebrospinal fluid. An
increase in one of these components, such as blood, from an intracranial haemorrhage, will need to be
compensated by a decrease in one or more of the other components.8 Initially, this increase in volume
can be accommodated; however, once these compensatory mechanisms become exhausted, intracranial
pressure will rise.8 This may result in the brain tissue shifting and becoming displaced (known as brain
herniation), which if left untreated can lead to respiratory depression and ultimately death.
Management of TBI is concerned with reducing intracranial pressures and can be broadly classified as
either surgical or medical. Surgical interventions include draining cerebrospinal fluid and decompressive
craniectomy.9 This involves removing a portion of the skull to relieve intracranial pressure. Medical options
include therapeutic hypothermia, sedation and analgesia, hyperosmolar therapy and hyperventilation.9
Many of the current TBI management options require skilled medical professionals and specialist
health-care facilities.
An inexpensive, simple and widely practicable treatment that improves outcomes in patients with TBI
could save many thousands of lives and reduce the burden of disability.

Tranexamic acid and traumatic brain injury
Tranexamic acid (TXA) is an antifibrinolytic drug that inhibits the enzymatic breakdown of fibrin blood
clots. It is possible that early administration of TXA in patients with TBI might prevent or reduce
intracranial haemorrhage expansion and thus avert brain herniation and death.
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Approximately one-third of patients with TBI have laboratory evidence of abnormal coagulation at hospital
admission.10 These patients have an increased risk of intracranial haemorrhage and higher mortality.
Increased clot breakdown (fibrinolysis), as indicated by elevated levels of fibrinogen degradation products,
is often seen in patients with TBI and predicts intracranial haemorrhage expansion.11
In addition, it has been shown that progressive tissue damage and oedema develop in regions
surrounding intracranial bleeding lesions, and are associated with worse outcomes.12 Tissue
plasminogen activator (tPA) has been shown to be an important factor in this process of perilesional
oedema.13–15 By blocking the conversion from plasminogen to plasmin, TXA counteracts the effect
of tPA and, therefore, it is possible that TXA might also be beneficial in traumatic intracerebral
haemorrhage by decreasing perilesional oedema through a specific neuroprotective effect.

Existing research on tranexamic acid
Tranexamic acid is commonly given to surgical patients to reduce bleeding and the need for blood
transfusion. A systematic review of randomised trials of TXA in elective surgical patients shows that
TXA reduces the number of patients receiving a blood transfusion by about one-third, reduces the
volume of blood transfused by about 1 unit and halves the need for further surgery to control
bleeding.16 These differences are all highly statistically significant. Furthermore, there is no evidence
of any increased risk of vascular occlusive events with TXA.16
More recently, the CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage-2)
trial17,18 showed that, in trauma patients with significant extracranial bleeding, early administration
(within 3 hours of injury) of TXA reduces bleeding deaths by one-third. Subsequent analyses showed that
even a short delay in treatment reduces the benefit of TXA administration.19 Based on these results, TXA
was included in guidelines for the pre-hospital care of trauma patients, although patients with isolated
TBI were specifically excluded.
Two studies have evaluated the effect of TXA in TBI. The CRASH-2 Intracranial Bleeding Study20 was a
nested randomised trial conducted in 270 trauma patients who had evidence of TBI on a pre-randomisation
CT scan. A second scan was conducted 24–48 hours after randomisation. There was a reduction in
intracranial haemorrhage growth [risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.09], fewer
ischaemic lesions and lower all-cause mortality (RR 0.60, 95% CI 0.32 to 1.11) in TXA-allocated patients,
but these results were not statistically significant.20 A second randomised trial conducted in 240 patients
with isolated TBI also found reductions in haemorrhage growth (RR 0.56, 95% CI 0.32 to 0.97) and
mortality (RR 0.67, 95% CI 0.34 to 1.32) with TXA, but this trial did not collect data on ischaemic
lesions.21

Rationale for trial
Meta-analysis of the two trials shows a significant reduction in haemorrhage growth (RR 0.72, 95% CI
0.55 to 0.94) and mortality (RR 0.63, 95% CI 0.40 to 0.99) with TXA. However, the studies provided no
evidence about the effect of TXA on disability or adverse events. The CRASH-3 (Clinical Randomisation
of an Antifibrinolytic in Significant Head Injury-3) trial aimed to quantify the effects of TXA on head
injury death, disability and adverse events in patients with TBI.19 We also wanted to assess the
cost-effectiveness of treating TBI patients with TXA.
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Chapter 2 Methods

T

he trial protocol,22 statistical analysis plan23 and results24 have been previously published and parts
of these published articles are reproduced throughout this report. The protocol was published in Trials
(reproduced from Dewan et al.22). This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. The text below
includes minor additions and formatting changes to the original text. The statistical analysis plan was
published in Wellcome Open Research (© 2018 Roberts et al.23 This is an open access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text).
The trial results were published in The Lancet [copyright © 2019 the CRASH-3 trial collaborators.24 This is
an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text].
The protocol and statistical analysis plan can be found at www.journalslibrary.nihr.ac.uk/programmes/
hta/1419001/#/documentation (accessed November 2020).

Trial design
CRASH-3 is an international, multicentre, randomised, placebo-controlled trial of the effects of TXA on
death and disability in patients with TBI. The trial protocol was peer reviewed and published in BioMed
Central Trials journal as an open access article in 2012 (see the trial protocol).22
CRASH-3 is the third international, multicentre, randomised, placebo-controlled trial in trauma patients
conducted by the London School of Hygiene & Tropical Medicine (LSHTM) trial co-ordinating centre.
CRASH-1 investigated corticosteroid use in head injury and recruited 10,000 patients with TBI from
across the world.7 CRASH-217 examined the effects of early administration of a short course of TXA in
trauma patients. The trial recruited 20,211 patients from 274 hospitals in 40 countries.
Through these many years of collaboration, LSHTM has developed good working relationships with a
large number of trauma doctors and an excellent global network of collaborating trauma hospitals.
CRASH-3 was undertaken in 175 hospitals in 29 countries. Suitable collaborating hospitals and investigators
were assessed in terms of the trauma service that they provide and their ability to conduct the trial. Before
the trial could begin at any site, the local principal investigator must have agreed to adhere to good
clinical practice guidelines and all relevant national regulations. In addition, all relevant regulatory and
ethics approvals were in place before the trial started at a site. See Appendix 1 for a list of the trial
collaborators by country.
There is a wide spectrum of treatments for TBI. As the trial was conducted worldwide, each
participating site was instructed to follow its own clinical guidelines for the treatment of TBI patients.
No clinically indicated treatment was required to be withheld for the trial. TXA or placebo was
provided as an additional treatment to the usual management of TBI.

Approvals
The Medical Research and Ethics Committee and Health Research Authority reviewed the protocol and
supporting documents for the CRASH-3 trial and provided a favourable ethics opinion on 19 July 2012
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(Research Ethics Committee reference 12/EE/0274). One substantial amendment to the protocol was
submitted to limit the time window for eligibility from within 8 hours of injury to within 3 hours of injury.
Favourable opinion was received on 6 September 2016. Two non-substantial amendments were submitted
to extend the recruitment period, and were categorised on 1 August 2017 and 2 February 2018. The
Medicines and Healthcare products Regulatory Agency authorised the CRASH-3 trial on 8 August 2012
(reference 17072/0007/001-0001). A favourable ethics opinion was received from the Observational/
Interventions Research Ethics Committee at LSHTM on 17 November 2011 (reference 6060).

Participants (inclusion and exclusion)
Adults with TBI who were within 3 hours of injury and had a GCS score of ≤ 12 or any intracranial
bleeding noted on their CT scan and no significant extracranial bleeding (i.e. not in need of immediate
blood transfusion) were eligible. The time window for eligibility was originally within 8 hours of injury;
however, in 2016, the protocol was changed to limit the time window for eligibility from within 8 hours
to within 3 hours of injury. This change was made blind to the trial data, in response to external
evidence suggesting that delayed treatment is unlikely to be effective.
The fundamental eligibility criterion was the responsible clinician’s ‘uncertainty’ about whether or
not to use TXA in a particular patient with TBI. This is based on the uncertainty principle, which
is a well-established approach for assessing trial eligibility.25 A patient can be enrolled if, and only
if, the responsible clinician is substantially uncertain as to which of the trial treatments is most
appropriate for that particular patient. A patient should not be enrolled if the responsible clinician or
the patient (or his/her representative) is, for any medical or non-medical reasons, reasonably certain
that one of the treatments that might be allocated is inappropriate for that particular individual
(in comparison with either no treatment or some other treatment that could be offered to the patient
in or outside the trial). Using the uncertainty principle allowed the process of this trial to be closer
to what is appropriate in normal medical practice. The pragmatic design allowed us to find out how
effective the treatment actually is in routine everyday practice.

Consent
Owing to the nature of their injury, most TBI patients are unable to provide prior informed consent
to participate in a clinical trial. As acknowledged in the Declaration of Helsinki,26 patients who are
incapable of giving consent are an exception to the general rule of informed consent in clinical trials.
In the CRASH-3 trial, consent was usually sought from the patient’s relative or a legal representative.
If no such representative was available, the study proceeded with the agreement of two clinicians
(one independent of the trial). If and when the patient regained capacity, they were told about the trial
and written consent was sought to continue participation. If the patient or their representative declined
consent, participation stopped. If patients were included in the trial but did not regain capacity, consent
was sought from a relative or legal representative. We adhered to the requirements of the local and
national ethics committees. See Appendix 2 for an overview of the consent procedure.

Randomisation and blinding
Sites were advised to randomise patients who were eligible for inclusion as soon as possible. The entry
form was used to assess eligibility and collect baseline information. Following confirmation of eligibility,
patients were randomly allocated to receive TXA or matching placebo (0.9% sodium chloride) by intravenous
(i.v.) infusion. An independent statistician from Sealed Envelope Ltd (London, UK) prepared the randomisation
codes and gave them to the drug packers so that treatment packs could be prepared. After baseline
information was collected on the entry form, the lowest numbered treatment pack remaining was taken
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from a box of eight treatment packs. If the treatment ampoules were intact, the patient was considered
randomised. Entry form data were entered into a secure online database by the trial investigators. Both
participants and study staff (site investigators and trial co-ordinating centre staff) were masked to allocation.
An emergency unblinding service was available for use in those rare situations when the clinician believed
that clinical management depended on knowledge of whether the patient received TXA or placebo.
The TXA (Cyklokapron® injection) was manufactured by Pfizer Ltd (Sandwich, UK). The Torbay and
South Devon NHS Foundation Trust prepared the 0.9% sodium chloride placebo. Ampoules and packaging
were identical in appearance. The blinding was done by Bilcare GCS (Europe) Ltd (Crickhowell, UK).
This entailed removal of the manufacturer’s label and replacement with the trial label and treatment
pack number. Pack label texts were identical for TXA and placebo. We checked the coding of the
blinded ampoules by randomly testing each batch of treatments and doing high-performance liquid
chromatography to determine the contents.

Trial intervention
Patients were randomly allocated to receive a loading dose of 1 g of TXA infused over 10 minutes,
started immediately after randomisation, followed by an i.v. infusion of 1 g over 8 hours, or matching
placebo. Every patient was assigned a treatment pack with a unique number, which contained four
ampoules of either 500 mg of TXA or placebo, one 100-ml bag of 0.9% sodium chloride (to use with
the loading dose), a syringe and needle, stickers with the trial details and randomisation number
(for attaching to the infusion bags, forms and medical records), and instructions. We separately
provided information for patients and representatives, consent forms and data collection forms.
The stickers, instructions, leaflets and forms were in local languages.

Dose selection
Tranexamic acid has been used to reduce bleeding in elective surgery for many years. A systematic
review of randomised trials of TXA in surgery shows that dose regimens of TXA vary widely.16 Loading
doses range from 2.5 mg/kg to 100 mg/kg and maintenance doses range from 0.25 mg/kg/hour to
4 mg/kg/hour delivered over periods of 1 to 12 hours. Studies examining the impact of different doses
of TXA on bleeding and transfusion requirements showed no significant difference between a high
dose and a low dose.16,27 In emergency situations, the administration of a fixed dose is more practicable
because weighing patients in such situations is difficult. In the CRASH-3 trial, a fixed dose of 1-g loading
dose of TXA, followed by a 1-g maintenance dose over 8 hours was selected. This fixed dose is within
the dose range that has been shown to inhibit fibrinolysis and provide haemostatic benefit. It should be
efficacious for heavier patients (> 100 kg) but also safe for lighter patients (< 50 kg), as the estimated
dose/kg that the latter group would receive has been used in other trials without adverse effects.
Furthermore, this fixed dose was used for 20,211 patients enrolled in the CRASH-2 trial and was found
to be both effective and safe.17 The same fixed dose was also used in two studies of TXA in TBI patients,
again with no evidence of adverse effects.20,21

Sites
We recruited patients with TBI from 175 hospitals in 29 countries. We enrolled the first patient on
20 July 2012 and the last patient on 31 January 2019. We stopped recruiting when the trial treatment
expired. See Appendix 3, Table 17, for the total number of randomisations by geographical region.
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Data collection
Baseline data
The trial entry form was used to collect baseline information including age, sex, time since injury,
systolic blood pressure (SBP), GCS score, pupil reaction and, if relevant, the location of intracranial
haemorrhage.

Outcome data
An outcome form was required to be completed 28 days after randomisation, or at death or hospital
discharge if either event had already occurred. Once randomised, outcome data were collected even
if the trial treatment was interrupted or not actually given. Short-term disability was assessed on the
outcome form using the Disability Rating Scale (DRS). This scale measures the level of disability in six
diagnostic categories of (1) eye opening, (2) best verbal response, (3) best motor response, (4) self-care
ability for feeding, grooming and toileting, (5) level of cognitive functioning and (6) employability, and it
can be used across the span of recovery. The maximum score a patient can obtain is 29, which represents
an extreme vegetative state. A person without disability would score zero.28 Specific patient-orientated
outcomes were also assessed. These measures were identified from the literature and then considered
and agreed by patient representatives from RoadPeace (London, UK), the UK national charity for those
killed or injured in road crashes.

Monitoring
As the trial was assessed as low risk (TXA is widely used and the trial was considered to have a
low risk of bias), central trial monitoring and central statistical monitoring were used in conjunction
with investigator training, meetings and written guidance. Trial investigators and their institutions
provided direct access to the source data for trial-related monitoring, audits and regulatory
inspections. We planned to monitor about 10% of patient records on site; however, after changing
the primary outcome, we expanded our monitoring plan to include patients enrolled within
3 hours of injury who subsequently died. We monitored 2436 (19%) patient records on site or
remotely (using video call or telephone). This included 1161 (67%) of the patients who died from
head injury (the primary outcome). The team of monitors worked alongside local trial teams to
verify data from the source data, including pre-hospital ambulance cards, admission registers,
emergency department notes, CT scans, surgery notes, blood transfusion registers, death registers
and death certificates.

Outcome measures
Primary outcome
The primary outcome was head injury death in hospital within 28 days of injury in patients randomised
within 3 hours of injury. The primary end point was originally 8 hours but, in 2016, the protocol was changed
to patients treated within 3 hours of injury. Cause of death was assessed by the responsible clinician.

Secondary outcome
Secondary outcomes were early head injury death (within 24 and 48 hours after injury), all-cause
and cause-specific mortality, disability, vascular occlusive events [myocardial infarction (MI), stroke,
deep-vein thrombosis (DVT), pulmonary embolism (PE)], seizures, complications, neurosurgery,
days in intensive care unit and adverse events within 28 days of randomisation. A diagnosis of
DVT or PE was recorded only if there was a positive result on imaging (e.g. ultrasound) or at
post-mortem examination.

6
NIHR Journals Library www.journalslibrary.nihr.ac.uk

DOI: 10.3310/hta25260

Health Technology Assessment 2021 Vol. 25 No. 26

Adverse events
Tranexamic acid has a well-documented safety profile. Although the summary of product characteristics29
suggests that rare cases of thromboembolic events might be associated with TXA administration, there
is no evidence that the TXA treatment regimen used in this trial is associated with an increased risk of
vascular occlusive events. Nevertheless, data on vascular occlusive events and seizures were collected as
secondary outcomes and presented to the independent Data Monitoring Committee for unblinded review.

Change to the protocol
In September 2016, in response to evidence external to the trial indicating that TXA is unlikely to be
effective when initiated beyond 3 hours of injury, the Trial Steering Committee (TSC) amended the protocol
to limit recruitment to within 3 hours of injury.18,30,31 Consequently, the primary end point was changed to
‘head injury death in hospital within 28 days of injury for patients treated within 3 hours of injury’.
To ensure that the trial would be large enough to reliably confirm or refute an early (< 3 hours)
treatment benefit, the sample size was increased from 10,000 to 13,000 patients with the aim of
enrolling 10,000 patients within 3 hours of injury.
The changes were made without reference to the unblinded trial data. The Data Monitoring Committee
was not consulted about the change. The change was therefore not driven by the unblinded trial data
seen by the Data Monitoring Committee, but instead driven by accumulating evidence external to the
trial. The trial was conducted in accordance with International Conference on Harmonisation-Good
Clinical Practice Guidelines.32

Rationale for protocol change
During the CRASH-3 trial, new research emerged suggesting that TXA is likely to be most effective in
the first few hours after injury and less effective when given later.18 Trauma triggers the early release of
tPA, the enzyme that converts plasminogen to the fibrinolytic enzyme plasmin, resulting in increased clot
breakdown and bleeding.33,34 tPA levels peak about 30 minutes after injury and plasmin peaks at 1 hour.34
By inhibiting early fibrinolysis, TXA prevents coagulopathic bleeding;35 however, the effects appear to be
short lived. Around 2 hours after injury, plasminogen activator inhibitor (PAI-1) levels increase, reaching a
peak at 3 hours.34 Plasminogen activator inhibitor inhibits fibrinolysis, resulting in ‘fibrinolytic shutdown’.36
This might explain why the benefits of TXA in polytrauma patients appear to be limited to the first
3 hours.18 As recent research shows that the coagulopathy after TBI is similar to that in poly-trauma,
a similar time-dependent effect might be expected after TBI.37,38 If the pathophysiological mechanisms
affected by TXA are most relevant in the early hours after injury, the effect of TXA in this early period is
the outcome of greatest importance. Nevertheless, intracranial bleeding can continue for up to 24 hours
after injury and, therefore, examination of the effects of TXA within and beyond 3 hours remains an
important scientific objective that will be addressed in preplanned subgroup analyses.

Sample size
Prior to implementing the amendment on limiting recruitment to within 3 hours of injury, 3535
participants had been recruited. It was originally estimated that a trial with about 10,000 patients
would have 90% power (two-sided alpha of 1%) to detect a 15% relative reduction (20% to 17%) in
mortality. We increased the sample size to 13,000 to get enough patients (about 10,000 as per
the original sample size calculation) within 3 hours of injury to confirm or refute an early benefit.
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With 10,000 patients, the study would also have > 90% power to detect a difference in mean DRS
score of 1.0 [assuming a standard deviation (SD) of DRS score of 9.0]. Experience from the CRASH-1
and CRASH-2 trials suggests that the anticipated rates of loss to follow-up (< 1%) would not have an
important impact on study power.17,39

Statistical methods and analysis plan
The statistical analysis plan was published before unblinding (see www.journalslibrary.nihr.ac.uk/
programmes/hta/1419001/#/documentation; accessed November 2020).19 The plan gave our reasons
for limiting recruitment to within 3 hours of injury and stated that outcomes for patients treated after
3 hours of injury would be presented separately. All analyses were on an ‘intention-to-treat’ basis.
For each binary outcome, we calculated RRs and 95% CIs. We conducted a complete-case analysis
with no imputation for missing data. The safety of participants was overseen by an independent Data
Monitoring Committee, which reviewed four unblinded interim analyses.

Subgroup analyses
In order to test the hypothesis that TXA is most effective when given soon after injury, a subgroup
analysis was conducted of the effect of TXA according to the time interval between injury and TXA
treatment (≤ 1 hour, > 1 to ≤ 3 hours, > 3 hours). We prespecified that this analysis would include
patients treated within and beyond 3 hours of injury. As TBI severity, SBP and age could confound the
impact of time to treatment on treatment effectiveness, we planned to control for these variables in a
multivariable model. We expected that any beneficial effect of TXA would vary by time to treatment,
with earlier treatment being most effective. We examined this hypothesis in a subgroup analysis of the
effect of TXA according to the estimated time interval between injury and treatment (≤ 1 hour, > 1 to
≤ 3 hours, > 3 hours).
The effects of TXA on the primary outcome were also stratified by severity of head injury and age.
Severity of head injury was assessed using the baseline GCS score, mild to moderate (GCS score of 9–15)
or severe (GCS score of 3–8), and by pupil reactivity. In addition, we assessed the impact of severity in a
regression analysis that included continuous terms for GCS and its square.
Traumatic brain injury patients who have a GCS score of 3 and bilateral unreactive pupils have a very
poor prognosis, with a mortality risk of about 75%. The inclusion in the CRASH-3 trial of such severely
injured patients, who may have little potential to benefit from the trial treatment, would bias the
treatment effect towards the null. We therefore prespecified a sensitivity analysis that excluded
patients with a GCS score of 3 and bilateral unreactive pupils.
As fibrinolytic activation after TBI may increase with age, we examined the effect of TXA on head
injury death stratified by age: younger (≤ 30 years), middle (31–60 years) and older (> 60 years).
For subgroup analyses, we report p-values for the test for heterogeneity.

Economic evaluation methods
An economic model was developed to analyse the cost-effectiveness of TXA treatment versus no
treatment for patients with TBI. The analysis was performed in line with National Institute for Health
and Care Excellence (NICE) guidance for economic evaluations, comparing the incremental costs and
outcomes associated with providing TXA, over a lifetime time horizon, from the perspective of the
UK NHS.40 Full details of the methods and results are provided in Chapter 5.
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Patient and public involvement
The CRASH-3 trial included patient and public involvement (PPI) to achieve the following objectives,
namely to:
l
l
l
l
l
l

gain a lay perspective on PPI involvement in the design and management of emergency care
clinical trials
identify an appropriate consent procedure for entering critically ill trauma patients into emergency
clinical trials, which could be used for CRASH-3
ensure that we collect outcomes that are of primary concern to patients and their families after TBI
ensure that patient-facing documents for the trial were appropriate and clear
provide a lay perspective on the management of the trial and interpretation of the results
assist in developing and implementing the results dissemination strategy, and to help with
presenting the trial results in a public-friendly format.

We included PPI groups to input to different stages of the trial. This included people who are at high
risk of TBI, charitable organisations that support victims of trauma (RoadPeace) and people who have
suffered TBI (Headway, Nottingham, UK).
Prior to working with our group, we carried out formative research to help guide PPI activities.

Formative research
Method
A qualitative study was conducted to elicit views on how best to involve patients and the public in the
design, conduct and reporting of clinical trials involving people in emergency situations, gathering
perspectives on which areas of the research programme they believed public contribution would be
most appropriate. Approaches to designing a consent process to enter patients into emergency clinical
trials were also explored.
Three focus group discussions were conducted, one with young people involved in an amateur boxing club,
the other with a group of older men belonging to a social club and the third with a group of older women
who were involved in a continuing education project and crafts-based activities. In total, 19 people took
part (12 men and 7 women).
The sessions included a PowerPoint® (Microsoft Corporation, Redmond, WA, USA) presentation
detailing why clinical trials are conducted in emergency medicine, how they are conducted and the key
principles, including issues of consent, randomisation and the use of placebos. This was followed by
three exercises using group work and discussion techniques.
Two key areas of inquiry emerged from these discussions: public involvement in the design and
management of clinical trials and decisions about entering patients into clinical trials in an emergency.

Involvement in clinical trial design and management
Participants were highly supportive of clinical medical research, seeing it as essential for the progress
of medical science. They also had a sense that the public should be consulted in principle. However,
they struggled to identify how they might usefully contribute to the design and management of clinical
trials in practice, seeing this as the province of highly skilled and qualified experts. Although there
were individuals who could envisage a role for themselves with appropriate information and preparation,
it was important to acknowledge that others felt that they had neither the inclination nor the aptitude to
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become involved, trusting in the expertise and competence of clinical researchers. Participants did have
strong opinions in one area: that decision-making about the outcomes of clinical research must take
account of quality-of-life issues and not be confined to treatment efficacy or safety, which they saw
patients and the public as being well placed to comment on.

Consent process for involving patients in clinical trials in an emergency
Initially, a minority opposed entering patients into trials without their consent but these views tended
be modified as participants considered the comments of others about the incapacitation of patients,
the time-critical nature of emergency medicine and the necessity of clinical trials for medical progress.
Overall, among all groups, there was a very high regard for the medical profession and a strong faith in
the skills and competence of medics, as well as the belief that clinicians would always act in the best
interest of the patient. This was reflected in a sense that clinicians should be allowed to exercise their
clinical judgement without undue burden to seek consent from next of kin when patients could not
consent for themselves. However, moderating this perspective for some was a belief in the principle
that, where practicable, next of kin should be consulted. Others argued that this might place a heavy
burden of responsibility on families, and that the clinician’s greater expertise may in fact render
better decisions.
Interestingly, when the participants were asked what they would want for themselves, all the
participants expressed a desire for the clinician (or their family) to enter them into the trial.

Patient and public involvement group
The PPI group was responsible for providing input on the development of quality-of-life outcome
measures to be used in the trial. They provided feedback from individuals with TBI and their caregivers
on items of primary concern to patients after TBI
The PPI group reviewed drafts of the patient representative and patient information sheets, and
consent forms.
A member of the PPI group from RoadPeace provided a lay perspective on the management of the
trial as part of the TSC. RoadPeace is the national charity for road crash victims in the UK. Road traffic
collisions are responsible for the majority of cases of TBI globally. RoadPeace supports survivors and
their families and works to prevent serious injury and deaths from road crashes.
RoadPeace provided input in the CRASH-3 dissemination strategy (see Chapter 7). RoadPeace was
involved in interpreting the data as part of the writing committee responsible for the main result
publication. Both RoadPeace and Headway (National Head Injuries Association) provided help in
dissemination of the results. A film to report the main trial results was led by a member of Headway
(https://crash3.lshtm.ac.uk/blog/crash-3-trial-results/; accessed 23 February 2020).

Outcome of patient and public involvement
Patient and public involvement contributed to the success of the trial. The consent process that was
developed with PPI groups was used in all countries that took part in the trial. The main structure and
content of the brief information sheet, participant/legal representative information sheets and consent
forms were utilised globally. They were accepted by all ethics committees and regulatory agencies with
only local modifications needed.
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The outcome measure developed with the PPI group included the following domains, which were
considered to be important to TBI patients and their families: (a) walking, (b) washing/dressing,
(c) pain/discomfort, (d) anxiety/depression, (e) agitation/aggression and (f) fatigue. A three-point scale
response for each domain was used (none, moderate, extreme).

Role of funding source
The run-in phase (the first 500 patients) was funded by the JP Moulton Charitable Trust. The main
phase was funded jointly by the National Institute for Health Research Health Technology Assessment
(HTA) (project number 14/190/01) and Joint Global Health Trials [Medical Research Council (MRC),
Department for International Development, Wellcome Trust] (project number MRM0092111).
Dr Paul Atkinson, Saint John Regional Hospital, Canada, received a CA$10,000 grant from the New
Brunswick Trauma Program to support the trial in Canada. The funders of the study had no role in
study design, data collection, data analysis, data interpretation or writing the report. The corresponding
author/writing committee had full access to all the data in the study and had final responsibility for the
decision to submit for publication.

Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

11

DOI: 10.3310/hta25260

Health Technology Assessment 2021 Vol. 25 No. 26

Chapter 3 Baseline results

T

he first patient was randomised on 20 July 2012 and the last patient on 31 January 2019.
Recruitment ended when the trial treatment expired.

Figure 1 shows the trial profile. A total of 12,737 patients were randomly allocated to receive TXA (6406
patients) or matching placebo (6331 patients). A total of 9202 patients were enrolled within 3 hours of injury.
Forty patients withdrew consent after randomisation, but 13 of them agreed to outcome data collection or
had outcome data collected as part of adverse event reporting. We did not obtain primary outcome data for
75 patients (0.8%). There were 98 protocol violations. Sixty-six patients did not meet the inclusion criteria
(32 patients had a GCS score of > 12 and no bleeding on CT scan, 11 had significant extracranial bleeding,
eight had a time since injury of > 8 hours, six were aged < 16 years, three had non-traumatic bleeding, five
had a combination of the above reasons, and one patient received TXA before randomisation). Thirty-two
patients were recruited during a lapse in ethics approval in country. These patients were recruited in
accordance with the approved procedure and approval was reissued after the lapse. Thirteen patients
were unblinded. Baseline characteristics were similar between treatment groups for patients treated
within 3 hours of injury (Table 1) and for those treated after 3 hours (Table 2).

Randomised
(n = 12,737)

Allocated to TXA group
(n = 6406)
• Randomised within 3 hours, n = 4649

Allocated to placebo group
(n = 6331)
• Randomised within 3 hours, n = 4553

Baseline data collected
(n = 6406)
• Randomised within 3 hours, n = 4649

Baseline data collected
(n = 6331)
• Randomised within 3 hours, n = 4553

Received loading dose
(n = 6314)
• Randomised within 3 hours, n = 4576

Received loading dose
(n = 6247)
• Randomised within 3 hours, n = 4488

Received maintenance dose
(n = 5984)
• Randomised within 3 hours, n = 4308

Received maintenance dose
(n = 5882)
• Randomised within 3 hours, n = 4191

Consent withdrawn
(n = 16)
• Randomised within 3 hours, n = 13

Consent withdrawn
(n = 24)
• Randomised within 3 hours, n = 19

Outcome data unavailable
(n = 9)
• Randomised within 3 hours, n = 7

Outcome data unavailable
(n = 18)
• Randomised within 3 hours, n = 14

Lost to follow-up
(n = 38)
• Randomised within 3 hours, n = 29

Lost to follow-up
(n = 33)
• Randomised within 3 hours, n = 25

Patients with outcome data
(n = 6359)
• Randomised within 3 hours, n = 4613

Patients with outcome data
(n = 6280)
• Randomised within 3 hours, n = 4514

FIGURE 1 Trial profile.
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TABLE 1 Baseline characteristics in participants randomised within 3 hours of injury
TXA (N = 4649), n

%

Placebo (N = 4553), n

%

Male

3742

80

3660

80

Female

906

19

893

20

Unknown

1

<1

0

0

Mean (SD)

41.7

19.0

41.9

19.0

< 25

1042

22

996

22

25–44

1716

37

1672

37

45–64

1169

25

1184

26

≥ 65

722

16

701

15

1.9

0.7

1.9

0.7

Sex

Age (years)

Time since injury (hours)
Mean (SD)
≤1

877

19

869

19

> 1–2

2003

43

1889

41

> 2–3

1769

38

1795

39

SBP (mmHg)
< 90

89

2

85

2

90–119

1508

32

1490

33

120–139

1461

31

1504

33

≥ 140

1576

34

1466

32

15

<1

8

<1

495

11

506

11

Unknown
a

GCS score
3
4

213

5

213

5

5

163

4

172

4

6

221

5

232

5

7

311

7

294

6

8

354

8

315

7

9

335

7

292

6

10

371

8

364

8

11

375

8

390

9

12

476

10

478

10

13

297

6

312

7

14

526

11

458

10

15

484

10

492

11

Unknown

28

1

35

1

Pupil reaction
None react

425

9

440

10

One reacts

374

8

353

8

Both react

3706

80

3636

80

Unable to assess/unknown

144

3

124

3

a The GCS is a scoring system to assess a patient’s level of consciousness. The highest score is 15, and the lowest
score is 3. The GCS is used to classify the severity of brain injury: severe, GCS score of 3–8; moderate, GCS score of
9–12; mild, GCS score of 13–15.
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TABLE 2 Baseline charactersitics before randomisations of all participants and participants randomised beyond 3 hours
of injury
> 3 hours

All
TXA (N = 6406)

Placebo (N = 6331)

TXA (N = 1757)

Placebo (N = 1778)

n

%

n

%

n

%

n

%

Male

5104

80

5013

79

1362

78

1353

76

Female

1301

20

1318

21

395

22

425

24

Unknown

1

<1

0

0

0

0

0

0

Mean (SD)

43

19.8

43.1

19.7

46.4

21.3

46.2

21.1

< 25

1362

21

1326

21

320

18

330

19

25–44

2285

36

2264

36

569

32

592

33

45–64

1625

25

1613

25

456

26

429

24

≥ 65

1134

18

1128

18

412

23

427

24

Mean (SD)

2.9

3.2

2.9

2.3

5.5

5.2

5.4

2.9

≤1

877

14

869

14

–

–

–

–

1–3

3772

59

3684

58

–

–

–

–

3–8

1737

27

1760

28

1737

99

1760

99

>8

20

<1

18

<1

20

1

18

1

< 90

108

2

109

2

19

1

24

1

90–119

2001

31

1988

31

493

28

498

28

120–139

2107

33

2120

33

646

37

616

35

≥ 140

2167

34

2097

33

591

34

631

35

Unknown

23

<1

17

<1

8

<1

9

1

3

630

10

642

10

135

3

136

3

4

261

4

275

4

48

1

62

1

5

211

3

242

4

48

1

70

2

6

304

5

308

5

83

2

76

2

7

413

6

400

6

102

2

106

2

8

465

7

406

6

111

2

91

2

9

416

6

382

6

81

2

90

2

10

463

7

444

7

92

2

80

2

11

465

7

502

8

90

2

112

2

12

600

9

601

9

124

3

123

3

13

460

7

453

7

163

4

141

3

Sex

Age (years)

Time since injury (hours)

SBP (mmHg)

GCS scorea

continued
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TABLE 2 Baseline charactersitics before randomisations of all participants and participants randomised beyond 3 hours
of injury (continued )
> 3 hours

All
TXA (N = 6406)

Placebo (N = 6331)

TXA (N = 1757)

Placebo (N = 1778)

n

%

n

%

n

%

n

%

14

790

12

754

12

264

6

296

7

15

899

14

886

14

415

9

394

9

Unknown

29

<1

36

1

1

<1

1

<1

None react

536

8

575

9

111

6

135

8

One reacts

511

8

482

8

137

8

129

7

Both react

5174

81

5113

81

1468

84

1477

83

Unable to assess/unknown

185

3

161

3

41

2

37

Pupil reaction

a The GCS is a scoring system to assess a patient’s level of consciousnessness. The highest score is 15, and the lowest
score is 3. The GCS is used to classify the severity of brain injury: severe, GCS score of 3–8; moderate, GCS score of
9–12; mild, GCS score of 13–15.
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Chapter 4 Outcome and results

O

utcome data were available for 12,639 randomised patients (6359 patients allocated to the TXA
group and 6280 patients to the placebo group). For patients randomised within 3 hours of injury,
outcome data were available for 9127 patients (4613 patients allocated to the TXA group and 4514
patients to the placebo group). A total of 12,561 (98.6%) patients were known to have completed the
loading dose, and 11,866 (93.2%) patients completed the 8-hour maintenance dose.

Primary outcome
Figure 2 shows the number of deaths and cause of death by days since injury in all patients
randomised. There were 2560 deaths in total and the median time to death was 59 hours after injury
(interquartile range 20–151 hours). Among patients treated within 3 hours of injury, there were 1878
deaths overall. Appendix 4, Figure 12, shows the cumulative incidence of head injury death in patients
randomised within 3 hours of injury.
Table 3 shows the effect of TXA on head injury death in the 9127 patients randomised within 3 hours
of injury with outcome data. Among patients treated within 3 hours of injury, the risk of head injury
death was 18.5% in the TXA group versus 19.8% in the placebo group (855 vs. 892 events; RR = 0.94,
95% CI 0.86 to 1.02). In the prespecified sensitivity analysis that excluded patients with a GCS score of
3 or bilateral unreactive pupils at baseline, the results were 12.5% in the TXA group versus 14.0% in
the placebo group (485 vs. 525 events; RR = 0.89, 95% CI 0.80 to 1.00).

800
700

Number of deaths

600
500
Death due to head injury
Deaths due to all other causes

400
300
200
100
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Days since injury
FIGURE 2 Mortality by days since injury among all participants randomised.
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TABLE 3 Effect of TXA on head injury death in participants randomised within 3 hours of injury
TXA

Placebo

Head injury death

n

N

%

n

N

%

RR (95% CI)

All

855

4613

18.5

892

4514

19.8

0.94 (0.86 to 1.02)

Excluding GCS score of 3, both unreactivea

485

3880

12.5

525

3757

14.0

0.89 (0.80 to 1.00)

a Prespecified sensitivity analysis: excluding patients with a GCS score of 3 and those with bilateral unreactive pupils.

Subgroup analysis
The effect of TXA on head injury death stratified by baseline GCS and pupillary reactions was
examined (Figure 3). There was a reduction in the risk of head injury death with TXA in mild to
moderate head injury (RR 0.78, 95% CI 0.64 to 0.95), but in severe head injury (RR 0.99, 95% CI
0.91 to 1.07) there was no clear evidence of a reduction (p-value for heterogeneity = 0.030). When we
examined the impact of baseline GCS score in a regression analysis, there was evidence (p = 0.007)
that TXA is more effective in less severely injured patients. Among patients with reactive pupils, head
injury deaths were reduced with TXA (RR 0.87, 95% CI 0.77 to 0.98).
We examined the effect of TXA on head injury death stratified by time to treatment and recorded
no evidence of heterogeneity (p = 0.96). The RR of head injury death with TXA was 0.96 (95% CI
0.79 to 1.17) in patients randomised ≤ 1 hour after injury, 0.93 (95% CI 0.85 to 1.02) in those
randomised > 1 to ≤ 3 hours after injury and 0.94 (95% CI 0.81 to 1.09) in those randomised > 3 hours
after injury. However, as anticipated in the statistical analysis plan, patients treated soon after injury
often have more severe head injury and so the impact of time to treatment could be confounded
by severity.
Figure 4 shows the impact of time to treatment on the effect of TXA in patients with a mild or
moderate head injury and in those with severe head injury after adjusting for GCS score, SBP and age
in a multivariable model including all participants. Early treatment was more effective in patients with
mild or moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in
severe head injury (p = 0.73). The effectiveness of TXA by time to treatment stratified by severity is
further demonstrated in Figure 5. We recorded no evidence of heterogeneity in the effect of TXA by
patient age (p = 0.45).
We examined the effect of TXA on head injury death stratified by World Bank country income level
(high income vs. low and middle income). This analysis was not prespecified. Although the reduction in
the risk of head injury death with TXA was higher in high-income countries (RR 0.76, 95% CI 0.55 to
1.04) than in LMIC (RR 0.92, 95% CI 0.81 to 1.04), there was no statistical evidence of heterogeneity
by country income level (p = 0.258). As early head injury deaths are more likely than late head injury
deaths to result from intracranial haemorrhage, we examined the effect of TXA on head injury deaths
within 24 and 48 hours of injury. The RRs of head injury death were 0.81 (95% CI 0.69 to 0.95) and
0.89 (95% CI 0.79 to 1.02) within 24 and 48 hours, respectively. When patients with a GCS score of 3
and those with bilateral unreactive pupils at baseline were excluded, the corresponding values were
0.72 (95% CI 0.56 to 0.92) and 0.84 (95% CI 0.69 to 1.01).
The models are adjusted for GCS score, age and SBP. In patients with a mild and moderate GCS score
(9–15) there were 537 head injury deaths. In patients with a severe GCS score (3–8) there were 918
head injury deaths, excluding those with a GCS score of 3 and those with unreactive pupils.
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0.64 to 0.95
Severe (3–8)

689/1739 (39.6)

685/1710 (40.1)

0.99

0.91 to 1.07

Both react

440/3820 (11.5)
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FIGURE 3 Effect of TXA on head injury death stratified by baseline severity in participants randomised within 3 hours of injury.

1.1
1.0
0.85
0.90
0.95
Favours TXA
0.80
0.75

95% CI
GCS

Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

DOI: 10.3310/hta25260

p = 0.030

Mild to moderate (9–15)

Overall

RR
Placebo
TXA
(N = 4613), n/N (%) (N = 4514), n/N (%)
Subgroup

19

OUTCOME AND RESULTS

(b)
1.25

1.25

1.00

1.00

RR (95% CI)

RR (95% CI)

(a)

0.75

0.50

Mild and moderate GCS score
0

0.75

0.50

60
120
180
240
Time to treatment in minutes

Severe GCS score
0

60
120
180
240
Time to treatment in minutes

FIGURE 4 Effect of TXA on head injury death by severity and time to treatment in all participants with (a) mild and moderate
head injury; and (b) severe head injury. Dotted lines represent 95% confidence limits. Mild/moderate, n = 8107; severe, n = 2703.
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FIGURE 5 Effectiveness of TXA on head injury death vs. time to treatment stratified by severity in all patients. Severe,
n = 2703; both pupils react, n = 2204; moderate, n = 3897; mild, n = 4275.

Secondary outcomes
In patients randomised within 3 hours of injury, the RRs for non-head injury deaths and for all-cause
mortality were 1.31 (95% CI 0.93 to 1.85; 75 vs. 56 events) and 0.96 (95% CI 0.89 to 1.04; 930 vs.
948 events), respectively. The results for non-head injury deaths broken down by cause and all-cause
mortality in all patients randomised are presented in Table 4.
We assessed the effect of TXA on disability in survivors by comparing the mean DRS score (lower score
means less disabled) between the TXA and placebo groups. The scores were similar between groups
for patients treated within 3 hours of injury (mean = 4.99, SD = 7.6, for TXA group, vs. mean = 5.03,
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TABLE 4 Effect of TXA on non-head injury deaths and deaths from any cause in all patients

Cause of death

TXA group, N = 6359

Placebo group, N = 6280

n

n

%

%

RR (95% CI)

Bleeding

9

0.1

7

0.1

1.27 (0.47 to 3.41)

PE

9

0.1

7

0.1

1.27 (0.47 to 3.41)

10

0.2

4

0.1

2.47 (0.77 to 7.87)

9

0.1

3

0.0

2.96 (0.80 to 10.94)

Multiorgan failure

27

0.4

24

0.4

1.11 (0.64 to 1.92)

Aspiration/pneumonia

30

0.5

34

0.5

0.87 (0.53 to 1.42)

Sepsis

9

0.1

6

0.1

1.48 (0.53 to 4.16)

Cervical spine injury

3

0.0

4

0.1

0.74 (0.17 to 3.31)

16

0.3

11

0.2

1.44 (0.67 to 3.09)

1262

0.2

1298

0.2

0.96 (0.90 to 1.03)

Stroke
MI

Other
Any cause

SD = 7.6, for placebo group) and for those treated after 3 hours of injury (mean = 4.52, SD = 7.0 for TXA
group, vs. mean = 5.00, SD = 7.4 for placebo group). We also examined the effect of TXA on disability
(Table 5) using an outcome measure designed by patient representatives by estimating the RR of being
in the most extreme category for six areas of functioning: (1) walking, (2) washing, (3) pain and
discomfort, (4) anxiety or depression, (5) agitation or aggression and (6) fatigue. The prevalence of
disability among survivors was similar in the TXA and placebo groups.

Adverse events
The risk of vascular occlusive events and other complications was similar in the TXA and placebo
groups (see Table 5). There was no evidence that TXA increased fatal or non-fatal stroke (RR = 1.08,
95% CI 0.71 to 1.64). The risk of seizures was similar between groups (RR = 1.09, 95% CI 0.90 to 1.33).
The numbers of other adverse events were similar between groups (see Appendix 5, Table 18).

Unblinding
Clinicians requested unblinding of the treatment allocation for 13 patients after randomisation for the
following reasons: TXA became indicated after randomisation, n = 7; clinical management depended on
knowing the treatment allocation, n = 3; patient requested unblinding, n = 1; required for suspected
unexpected serious adverse reaction reporting, n = 1; unblinded in error, n = 1.
Forty patients received TXA in addition to the trial treatment after randomisation. In 36 cases, this was
because the clinician believed that it was clinically indicated, and in four cases it was given in error
instead of the trial drug.
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22

< 3 hours

≥ 3 hours

TXA
(N = 4613)

Placebo
(N = 4514)

n

%

n

%

All

TXA
(N = 1746)

Placebo
(N = 1766)

RR (95% CI)

n

%

n

%

TXA
(N = 6359)

Placebo
(N = 6280)

RR (95% CI)

n

%

n

%

RR (95% CI)

Patient-derived disability measuresa
Confined to bed

579

12.6

549

12.2

1.03 (0.93 to 1.15)

190

10.9

222

12.6

0.87 (0.72 to 1.04)

769

12.1

771

12.3

0.99 (0.90 to 1.08)

Unable to wash or dress

580

12.6

583

12.9

0.97 (0.87 to 1.08)

195

11.2

228

12.9

0.87 (0.72 to 1.04)

775

12.2

811

12.9

0.94 (0.86 to 1.03)

Extreme pain or discomfort

38

0.8

29

0.6

1.28 (0.79 to 2.08)

10

0.6

10

0.6

1.01 (0.42 to 2.42)

48

0.8

39

0.6

1.22 (0.80 to 1.85)

Extreme anxiety or
depression

43

0.9

41

0.9

1.03 (0.67 to 1.57)

19

1.1

20

1.1

0.96 (0.51 to 1.79)

62

1.0

61

1.0

1.00 (0.71 to 1.43)

Extreme agitation or
aggression

53

1.1

53

1.2

0.98 (0.67 to 1.43)

14

0.8

27

1.5

0.52 (0.28 to 1.00)

67

1.1

80

1.3

0.83 (0.60 to 1.14)

100

2.2

101

2.2

0.97 (0.74 to 1.27)

40

2.3

43

2.4

0.94 (0.61 to 1.44)

140

2.2

144

2.3

0.96 (0.76 to 1.21)

All vascular occlusive events

69

1.5

60

1.3

1.13 (0.80 to 1.59)

32

1.8

42

2.4

0.77 (0.49 to 1.21)

101

1.6

102

1.6

0.98 (0.74 to 1.28)

PE

18

0.4

18

0.4

0.98 (0.51 to 1.88)

6

0.3

14

0.8

0.43 (0.17 to 1.13)

24

0.4

32

0.5

0.74 (0.44 to 1.26)

DVT

15

0.3

12

0.3

1.22 (0.57 to 2.61)

4

0.2

4

0.2

1.01 (0.25 to 4.04)

19

0.3

16

0.3

1.17 (0.60 to 2.28)

Stroke

29

0.6

23

0.5

1.23 (0.71 to 2.13)

17

1.0

19

1.1

0.90 (0.47 to 1.74)

46

0.7

42

0.7

1.08 (0.71 to 1.64)

9

0.2

12

0.3

0.73 (0.31 to 1.74)

9

0.5

8

0.5

1.14 (0.44 to 2.94)

18

0.3

20

0.3

0.89 (0.47 to 1.68)

73

1.6

56

1.2

1.28 (0.90 to 1.80)

27

1.5

28

1.6

0.98 (0.58 to 1.65)

100

1.6

84

1.3

1.18 (0.88 to 1.57)

Sepsis

297

6.4

279

6.2

1.04 (0.89 to 1.22)

114

6.5

133

7.5

0.87 (0.68 to 1.10)

411

6.5

412

6.6

0.99 (0.86 to 1.12)

Seizure

130

2.8

105

2.3

1.21 (0.94 to 1.56)

76

4.4

81

4.6

0.95 (0.70 to 1.29)

206

3.2

186

3.0

1.09 (0.90 to 1.33)

16

0.3

22

0.5

0.71 (0.37 to 1.35)

8

0.5

13

0.7

0.62 (0.26 to 1.50)

24

0.4

35

0.6

0.68 (0.40 to 1.14)

Extreme fatigue
Complications

b

MI
Renal failure

Gastrointestinal bleeding

a Includes survivors only.
b Includes fatal and non-fatal events.
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Chapter 5 Economic evaluation results
Model analysis and model population characteristics
The cost-effectiveness analysis has been published in BMJ Global Health.41 Parts of this chapter have been
reproduced from Williams et al.41 in accordance with © Williams et al.41 [or their employer(s)] 2020.
[Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/. This is
an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported
(CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work
for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of
whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.]
The economic analysis assessed the cost-effectiveness of treating TBI patients with TXA and without
TXA, as per the trial treatment arms. The following health economic section has been reported to meet
the criteria of the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist.42
As stated above, the trial included patients treated within 3 hours of their injury with either a GCS score
of ≤ 12 or any intracranial bleeding on their CT scan, and without extracranial bleeding. The trial found
that TXA reduced head injury deaths among those with TBI, with a RR of 0.94 (95% CI 0.86 to 1.02).
However, there was evidence that people with mild or moderate TBI (baseline GCS score of 9–15) had
a greater benefit from TXA treatment, in terms of reduction in head injury death (RR 0.78, 95% CI
0.64 to 0.95), than those with a severe head injury (GCS score of 3–8; RR 0.99, 95% CI 0.91 to 1.07).
For this reason, the mild and moderate population was used as the base-case population, excluding those
with severe head injury. In addition to considering the cost-effectiveness of TXA based on baseline GCS
score, we also evaluated the cost-effectiveness of TXA for an alternative subgroup of patients: those
with head injury of any severity with both pupils reactive (RR 0.87, 95% CI 0.77 to 0.98), based on the
clinical results presented in Figure 3. We excluded those with either pupil unreactive (RR 1.03, 95% CI
0.94 to 1.13), as there was no evidence of a reduction in head injury deaths for this subgroup.
The model was analysed over a lifetime time horizon with costs presented in Great British pounds,
and outcomes presented as life-years (LYs) and quality-adjusted life-years (QALYs). The analysis was
performed from a UK NHS and personal social services perspective. The model estimates the incremental
cost-effectiveness ratio (ICER) by dividing the incremental costs of TXA by the incremental health outcomes
associated with TXA treatment, to give a cost per LY or QALY gained. We used the lower bound of the
£20,000 to £30,000 per QALY cost-effectiveness threshold stated by NICE to estimate the cost-effectiveness
of TXA.40 If the ICER falls below the cost-effectiveness threshold, then that intervention can be considered
cost-effective. Both costs and outcomes were discounted at a rate of 3.5%, in accordance with NICE
guidelines,40 to capture the higher value of current costs and outcomes compared with those occurring in
the future. The mean age of individuals entering the model was derived directly from the CRASH-3 trial
(41.7 years for patients with mild and moderate injury and 41.6 years for those with both pupils reactive).
Deterministic sensitivity analyses were performed, in which alternative discount rates (0% and 6%)
were evaluated. The cost-effectiveness model was developed in Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA), with the analysis of trial data performed in Stata® 16 (StataCorp LP, College
Station, TX, USA).
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Model structure
A Markov model captured the long-term outcomes associated with head injury, and is shown in Figure 6.
It consists of two health states, alive and dead, and includes the risk of death during the first 28 days of
the trial from both head injuries and non-head injuries along with estimates of longer-term mortality.
The model uses a daily cycle length for the first year, to allow the events during the trial period to be
accurately modelled, followed by an annual cycle length thereafter.

Clinical outcomes
The 28-day risk of head injury and non-head injury death for the placebo group were derived from
the CRASH-3 trial, with the risk in high-income countries used to estimate the risk in the UK. A RR
of head injury death was applied for patients receiving TXA, as derived directly from the CRASH-3 trial.
The risk of non-head injury death was equal for placebo and TXA groups in the model, based on the
CRASH-3 trial. The risk of head injury and non-head injury death within the 28-day follow-up period,
and the head injury rate ratio associated with TXA, are presented for the mild and moderate CRASH-3
population in Table 6 and for patients with both pupils reactive in Table 7.

Risk of head injury death
(multiplied by RR for TXA)
First 28 days
(CRASH-3 data)

Alive

Dead
Risk of non-head injury death

Post 28 days
(Data from literature)

Long-term risk of any death
(adjusted for age and elevated risk post TBI)
Alive

Dead

FIGURE 6 Model structure.

TABLE 6 Base-case risk of death and treatment effects for mild and moderate population
Parameter

Value

Distribution

Source

Head injury

0.78

Log-normal(µ = –0.248, σ = 0.1)

CRASH-324

Non-head injury

1

N/A

CRASH-324

Head injury death

0.061

Beta(α = 42, β = 643)

CRASH-324

Non-head injury death

0.018

Beta(α = 12, β = 673)

CRASH-324

First year, post injury

4.00

Normal(95% CI 3.27 to 4.90)

McMillan et al.43

Beyond first year, post injury

2.26

Normal(95% CI 1.84 to 2.77)

McMillan et al.43

TXA rate ratio treatment effect

28-day risk of death

Long-term standardised mortality ratios

N/A, not applicable.
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TABLE 7 Risk of death and treatment effect for mild and moderate CRASH-3 population with both pupils reactive
Parameter

Value

Distribution

Source

Head injury

0.87

Log-normal(µ = –0.138, σ = 0.06)

CRASH-324

Non-head injury

1

N/A

CRASH-324

Head injury death

0.105

Beta(α = 42, β = 643)

CRASH-324

Non-head injury death

0.019

Beta(α = 12, β = 673)

CRASH-324

First year, post injury

4.00

Normal(95% CI 3.27 to 4.90)

McMillan et al.43

Beyond first year, post injury

2.26

Normal(95% CI 1.84 to 2.77)

McMillan et al.43

TXA rate ratio treatment effect

28-day risk of death

Long-term standardised mortality ratios

N/A, not applicable.

Following the 28-day trial follow-up period, the risk of death was assumed equal for people treated
with and people treated without TXA. Standardised mortality ratios (SMRs) were used to account for
the higher risk of death post TBI compared with the general population. SMRs were derived from a
Scottish study that included a variety of head injury severities. It estimated a SMR of 4 for the first
year following injury, and 2.26 thereafter, compared with a group of matched community controls.43
These SMRs were applied relative to age-based, UK general population mortality estimates, and were
assumed to be the same for those with mild or moderate TBI and those with both pupils reactive.44
It was assumed that the additional long-term risk of death continued throughout the duration of the
model; however, a sensitivity analysis that excluded this long-term risk of death was performed, to
assess the impact of this parameter.

Health status, utility and quality-adjusted life-years
In the CRASH-3 trial, there was little difference between the DRS scores for each treatment arm
reported for those with mild or moderate TBI [TXA 3.12 (SD 5.6) vs. placebo 2.91 (SD 5.1), with lower
scores representing better outcomes] and those with both pupils reactive [TXA 4.38 (SD 7) vs. placebo
4.33 (SD 6.9)].
To capture the quality of life for patients post TBI, utility values for the ‘alive’ health state were
derived from a systematic review and EuroQol-5 Dimensions utility mapping study, which identified
five studies reporting utility values stratified by the severity of TBI outcomes.45 This mapping studies
then estimated utility by Glasgow Outcome Scale (GOS) outcomes, using a UK value set.45 The utilities
associated with each GOS outcome is shown in Table 8.45 In our analysis, we estimated the overall
utility by estimating the corresponding GOS outcome for each patient by using the DRS outcomes
reported in the CRASH-3 trial. The mapping of each DRS outcome to the GOS outcome is presented in
Appendix 6, Table 19. Once this mapping was performed, a weighted average of GOS outcomes was
used to estimate the average utility for each population. The average utility was 0.74 for the mild
and moderate population and 0.70 for those with both pupils reactive (Table 9). It was assumed that
individuals who died within the 28-day study period had a utility of 0 between their injury and death.
Owing to the uncertainty around the utility estimates used in the base-case analysis, three sensitivity
analyses were performed to consider the impact of alternative utility values on the cost-effectiveness of
TXA. First, a sensitivity analysis was performed in which the DRS scores for those receiving TXA and placebo
were modelled independently, and independently mapped to utility scores, which resulted in a marginally
lower utility among those receiving TXA. This resulted in utility values of 0.74 for TXA and 0.75 for placebo
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TABLE 8 Estimated distribution of GOS outcomes and associated utility distributions, by DRS scores

GOS outcomea

DRS scores

Mild/moderate
population (n)

Both pupils react
population (n)

Utility
value

Distribution

Good recovery

0–1

3094

3478

0.894

Beta(α = 50, β = 5.9)

Moderate disability

2–6

1288

1545

0.675

Beta(α = 30.5, β = 14.7)

Severe disability

7–21

677

1084

0.382

Beta(α = 10.9, β = 17.7)

Vegetative state

22–29

124

359

–0.178

Beta(α = 16.1, β = –106.3)

a GOS outcomes estimated from corresponding DRS scores.
Source: DRS scores utility values and distributions.45 Ward Fuller et al.45 is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes to the original table.

TABLE 9 Base-case model utilites
Population

Utility value

Mild/moderate TBI

0.74

Both pupils react

0.70

in the mild and moderate group, and 0.69 for TXA and 0.7 for placebo for patients with both pupils reactive.
Second, a sensitivity analysis considered an alternative method to estimate GOS outcomes among CRASH-3
patients, using a previous study reporting the correlation between GCS score at injury and GOS outcomes
(see Appendix 6, Table 20, for additional details).45,46 This allowed for the distribution of GCS scores for
patients in the CRASH-3 trial to be used to estimate the distribution of GOS outcomes, to which utility
values could be applied. This produced higher estimated utilities of 0.79 for the mild and moderate
population and 0.76 for patients with both pupils reactive (see Appendix 6, Table 21). Last, a sensitivity
analysis considered the impact of a lower utility value, of 0.63, for both treatment groups, and for both
model populations (patients with mild and moderate injury and patients with both pupils reactive), to assess
the impact of a lower utility estimate on cost-effectiveness. This was an average estimate derived from a
Swiss study of trauma patients reporting utility values in mild (0.7) and moderate (0.56) TBI patients, with
GCS score of 9–15, and with an abbreviated injury score of 0–2, representing mild or no TBI.47
Age-based utility estimates for the UK general population were used to account for the decline in utility
with age (Table 10).48 The post-TBI utility estimates (see Table 9) were derived from a cohort with a median
age of 50 years. Therefore, a utility decrement model population for those reaching the age of ≥ 55 years.
TABLE 10 UK general population utility values by age
Age (years)

Utility

Utility decrement

35–44

0.91

0

45–54

0.85

0

55–64

0.8

0.05

65–74

0.78

0.07

≥ 75

0.73

0.12

Source: Kind et al.48 and reproduced with permission from Williams et al.41 This is an open access article distributed in
accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy,
redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link
to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0/.
This includes minor additions and formatting changes to the original table.
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For example, the average utility for patients with mild or moderate TBI after discharge would be 0.75
until they reach 55 years, when the utility would decrease to 0.70 (0.75 minus 0.05). The utility would
then decrease to 0.68 at 65 years (0.75 minus 0.07). The utility estimates were not inflated between
42 (average starting age in the model) and 44 years, to remain conservative.

Costs
Treatment costs
The model captured the costs of TXA treatment, including the cost of TXA, needle and syringe, and
nurse administration time, which were applied to the TXA intervention only (see Table 14). The total
cost of TXA was derived from the British National Formulary49 (£6 per person), as were the costs of the
infusion bags (£3.25 for a 100-ml and 500-ml bag). The costs of needles and syringes were derived
from a NICE costing template for the UK.50
The nurse time required to administer TXA was assumed to be 21 minutes (as per the CRASH-218
economic analysis), and the hourly cost of a nurse was derived from UK social service costs, based
on the hourly cost of a band 5, hospital-based NHS nurse.51,52 This gave a total cost of £22.25 for
treatment, equipment and treatment administration.

Hospital costs
There was little difference in hospital length of stay for those treated with and those treated without
TXA in high-income countries [TXA 14 days (SD 9.8 days), placebo 13.3 days (SD 9.3 days), overall
13.7 days (SD 9.6 days)], and, therefore, this was assumed to be the same for both arms. A sensitivity
analysis was performed to assess this assumption, in which the trial data for hospital length of stay were
modelled specifically for each treatment arm. Inpatient hospital costs were derived from UK NHS reference
costs,53 using the cost associated with head injury admissions. A weighted average of all head injury admission
costs was calculated, based on the severity of the head injury (case mix adjusted). As the length of stay was
assumed to be the same for those treated with TXA and those treated without TXA, hospital costs did not
affect the incremental cost-effectiveness, except in the sensitivity analysis to assess this assumption.

Monitoring costs
Patients were assumed to incur additional health-care resources post discharge. These long-term
monitoring costs include the increased use of health services, such as outpatient clinic visits and more
frequent visits to GPs. It also includes rehabilitation and physiotherapy, and community care, such as
formal carers. These costs were assumed to differ between the first year post injury and after 12 months.
First-year monitoring costs were derived from a UK costing study,54 for those with good recovery,
moderate disability and severe disability. These costs were mapped from DRS scores (using the same
method described above to map from DRS to GOS outcomes) to estimate the average annual monitoring
costs (Table 11). These costs have also been used in a previous HTA analysis.55
The average first-year monitoring cost was estimated to be £11,662 for those with mild or moderate
head injury and £14,259 for those with both pupils reactive.54 Long-term monitoring costs (applied
after the first year post injury) were estimated by expert opinion in a previous HTA.55 The average cost
was £2505 per year for patients with mild or moderate TBI and £3405 for patients with both pupils
reactive, and was assumed to be incurred until the patient died. We explored the impact of excluding
monitoring costs beyond the first year post injury and applying monitoring costs until 5 years post
injury in sensitivity analyses, owing to the uncertainty in these estimates.
The average monitoring costs for the UK were estimated by combining the annual cost by GOS status
(see Table 11) with the proportion of patients across each GOS outcome (see Appendix 6, Table 19).
A weighted average was used to provide the average annual monitoring cost for each population,
as displayed in Table 12.
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TABLE 11 Mapping of DRS score to GOS scores to estimate monitoring costs, for first year after head injury

GOS status

Estimated equivalent
DRS scores

Cost, first
year (£)

Good recovery

0–1

£290

Gamma(k = 25,
θ = 9.6)

£26

Gamma(k = 25,
θ = 0.96)

Moderate disability

2–6

£20,745

Gamma(k = 25,
θ = 686)

£1710

Gamma(k = 25,
θ = 64)

Severe disability

7–21

£40,983

Gamma(k = 25,
θ = 1356)

£13,363

Gamma(k = 25,
θ = 500)

Vegetative state

22–29

£40,983a

Gamma(k = 25,
θ = 1356)

£13,363a

Gamma(k = 25,
θ = 500)

Distribution

Cost, after first
year (£)

Distribution

a Assumed equal to severe disability.
Source: first-year costs – Beecham et al.;54 post first-year costs – Lecky et al.55 (from expert opinion) (contains information
licensed under the Non-Commercial Government Licence v2.0); and reproduced with permission from Williams et al.41
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:
http://creativecommons.org/licenses/by/4.0/. This includes minor additions and formatting changes to the original table.

TABLE 12 Average monitoring costs, by CRASH-3 population, stratified by time since TBI
Population

Cost, 0–12 months (£)

Cost, > 12 months (£)

Patients with mild/moderate TBI

£11,662

£2505

Patients with both pupils reactive

£14,259

£3405

All costs for the mild and moderate TBI population are shown in Table 13, and for the both pupils
reactive population in Table 14. All costs were inflated to 2018 prices using a UK hospitals and
community service index.52

Sensitivity analyses
The main analysis was performed using probabilistic sensitivity analyses to simultaneously capture the
uncertainty in model parameters. Distributions were assigned to each probabilistic parameter, with
each sampled simultaneously across 1000 Monte Carlo simulations. One-way deterministic sensitivity
analyses were also performed to assess the sensitivity of specific parameters on the cost-effectiveness
estimates, and are presented relative to the base case as a tornado diagram.

Primary analysis of base-case incremental costs, quality-adjusted life-years
and incremental cost-effectiveness ratio: mild and moderate traumatic
brain injury patients
The costs, LYs and QALYs associated with TXA treatment and without TXA treatment are presented in
Table 15. In the base-case analysis, TXA is highly cost-effective in the UK for those with mild and those with
moderate TBI, at £4288 per QALY gained. When considering LYs only, the ICER was £3078 per LY gained.
The cost of purchasing and administering TXA represented a very small proportion of the incremental
costs (3%), with long-term monitoring costs contributing to most of the incremental costs for the TXA
group (97%). These higher costs are due to a higher proportion of patients surviving when given TXA,
as monitoring costs per person were the same in both treatment groups.
The long-term survival projections of the model for patients with mild or moderate TBI receiving TXA
or placebo are presented in Appendix 6, Figures 13 and 14.
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TABLE 13 Base-case model costs, for mild and moderate population
Parameter

Cost (£)

Distribution

Source

TXA (full dose)

£6.00

N/A

British National Formulary56

Sodium chloride

£3.25

N/A

British National Formulary57

Needle and syringe

£0.05

N/A

NICE50

Hospital cost

£4751

N/A

CRASH-324/Department of Health and
Social Care53

Monitoring costs (first year post injury)

£11662

By component
(see Table 11)

Lecky et al.,55 Beecham et al.54

Monitoring costs (after first year post injury)

£2505

By component
(see Table 11)

Lecky et al.55

N/A, not applicable.
Post first-year costs were derived from Lecky et al.,55 who used expert opinion to estimate costs (contains information
licensed under the Non-Commercial Government Licence v2.0).

TABLE 14 Base-case model costs, for both pupils react population
Parameter

Cost (£)

Distribution

Source

TXA (full dose)

£6.00

N/A

British National Formulary56

Sodium chloride

£3.25

N/A

British National Formulary57

Needle and syringe

£0.05

N/A

NICE50

Hospital cost

£5158

N/A

CRASH-324/Department of Health and
Social Care53

Monitoring costs (first year post injury)

£14,259

By component
(see Table 11)

Lecky et al.,55 Beecham et al.54

Monitoring costs (after first year post injury)

£3405

By component
(see Table 11)

Lecky et al.55

N/A, not applicable.
Post first-year costs were derived from Lecky et al.,55 who used expert opinion to estimate costs (contains information
licensed under the Non-Commercial Government Licence v2.0).

TABLE 15 Base-case cost-effectiveness results for mild and moderate TBI patients treated with TXA and without TXA
Treatment group

Cost (£)

LYs

QALYs

Placebo

£55,108

16.87

12.10

TXA

£55,867

17.12

12.28

ICER (per LY)

ICER (per QALY)

£3078

£4288

Sensitivity analyses of base-case population: mild and moderate traumatic
brain injury
Probabilistic sensivity analysis
Tranexamic acid was highly likely to be cost-effective in the probabilistic sensitivity analysis (PSA),
with a 99% probability of being cost-effective at the NICE £20,000 per QALY willingness-to-pay
threshold (Figure 7).

Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

29

ECONOMIC EVALUATION RESULTS

1.0
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FIGURE 7 Cost-effectiveness acceptability curve for TXA for patients with mild or moderate TBI.

Deterministic sensitivity analysis
A number of sensitivity analyses were performed, but none increased the ICER above the costeffectiveness threshold, meaning that TXA remained cost-effective in all deterministic sensitivity
analyses (Figure 8). Assuming a lower utility among those receiving TXA than among those receiving
placebo increased the ICER the most, to £14,465 per QALY. Restricting monitoring costs to only the
first year or first 5 years post injury reduces the ICER to £979 and £1646 per QALY, respectively.
When considering a longer length of hospital stay for those receiving TXA than for those receiving
placebo, the ICER increased to £5567, whereas assuming a lower utility (0.63 for both arms) increased
the ICER to £5112 per QALY. TXA remained cost-effective when the RR increased to 0.95, with the
ICER increasing to £4721 per QALY. The discount rate, and excluding excess mortality after the trial
period, had little impact on the ICER.

Analyses for patients with both pupils reactive: incremental costs,
quality-adjusted life-years and incremental cost-effectiveness ratio
Deterministic results
When considering individuals with both pupils reactive, treatment remained highly cost-effective with
an ICER of £6097 per QALY in the UK. When considering LYs only, the ICER was £4066 per LY gained
(Table 16).

Utility by arm (TXA, 0.74; placebo, 0.75)
Monitoring costs 1 year (post injury)
Monitoring costs until 5 years (post injury)
Hospital stay by arm (TXA, 14 days; placebo, 13.3 days)
Utility (0.74

Upper value/
scenario
Lower value

0.63–0.79, both arms)

Head injury RR (0.78

0.64–0.95)

Discount rate (3.5%

0–6%)

Excess mortality excluded
0

2000

4000

6000 8000 10,000 12,000 14,000 16,000
ICER per QALY (£)

FIGURE 8 Tornado diagram showing deterministic sensitivity analyses and the impact on the ICER per QALY gained,
for those with mild or moderate TBI.
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TABLE 16 Cost-effectiveness results for patients with both pupils reactive
Treatment group

Cost (£)

LYs

QALYs

Placebo

£68,894

16.04

10.69

TXA

£69,901

16.29

10.86

ICER (per LY)

ICER (per QALY)

£4066

£6097

Probabilistic sensitivity analysis
At the UK cost-effectiveness threshold of £20,000 per QALY, TXA is 99% likely to be cost-effective in
the PSA (Figure 9).

Deterministic sensitivity analysis
The deterministic results for patients with both pupils reactive show that, for all sensitivity analyses in
the UK, TXA remained highly cost-effective (Figure 10). Similarly to the results for the mild and moderate
TBI population, a reduction in monitoring costs being applied for either 1 year only or 5 years reduced
the ICER to £1257 and £2233 per QALY, respectively. Assuming a lower utility among those receiving
TXA than among those receiving placebo increased the ICER to £9512 per QALY. When assuming a
longer length of hospital stay for TXA based on the CRASH-3 trial, the ICER increased to £7804.
At a head injury treatment effect rate ratio of 0.98 (representing the upper 95% CI), TXA remained
cost-effective, with the ICER increasing to £6949 per QALY. The ICER also increased when considering a
lower utility (0.63), to £6753 per QALY. The discount rate, and excluding excess mortality after the trial
period, had little impact on the ICER.
1.0
Probability cost-effective

0.9
0.8
0.7
0.6
QALY
LY

0.5
0.4
0.3
0.2
0.1
0.0
0

5000

10,000

15,000

20,000

25,000

30,000

Willingness to pay (£)
FIGURE 9 Cost-effectiveness acceptability curve for TXA treatment for patients with both pupils reactive.

Monitoring costs 1 year (post injury)
Monitoring costs until 5 years (post injury)
Utility by arm (TXA, 0.69; placebo, 0.70)
Upper value/
scenario
Lower value

Hospital stay by arm (TXA, 15.4 days; placebo, 15 days)
Head injury RR (0.87
Utility (0.70

0.77–0.98)

0.63–0.76, both arms)

Discount rate (3.5%

0–6%)

Excess mortality excluded
0

2000

4000
6000
ICER per QALY (£)

8000

10,000

FIGURE 10 Tornado diagram showing deterministic sensitivity analyses and the impact on the ICER per QALY gained for
patients with both pupils reactive.
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Chapter 6 Discussion

T

his trial provides evidence that administration of TXA to TBI patients within 3 hours of injury reduces
head injury deaths, with no evidence of adverse effects or complications. There was a substantial
reduction in head injury deaths with TXA in patients with mild or moderate head injuries, but no apparent
reduction in those with severe head injuries. There was no increase in disability among survivors.
The effect of TXA on head injury death appears to depend on the time interval between injury and the
initiation of the trial treatment, and on the severity of the TBI. Early treatment of patients with mild
(GCS score of 13–15 and intracranial bleeding on baseline CT scan) and moderate head injury seems to
confer the greatest mortality benefit. This is consistent with the hypothesis that TXA improves outcomes
by reducing intracranial bleeding. As haemorrhage expansion occurs in the hours immediately after
injury, treatment delay would reduce the potential for TXA to prevent intracranial bleeding.5,6 Patients
with severe head injury may have less to gain from TXA treatment because they already have extensive
intracranial haemorrhage prior to treatment, or other potentially life-threatening intracranial pathologies
that are not affected by TXA. We anticipated in our statistical analysis plan that the effect of TXA would
be greatest for head injury deaths occurring in the first few days after injury than for later head injury
deaths, because early head injury deaths are more likely as a result of bleeding. Our data support this
hypothesis, showing a substantial reduction in head injury deaths within 24 hours of injury (RR 0.72,
95% CI 0.56 to 0.92). Similar results were obtained in the CRASH-2 trial35 of TXA in traumatic extracranial
bleeding, in which the effect of TXA on death from bleeding was greatest on the day of the injury
(RR 0.72, 95% CI 0.60 to 0.86). However, thereafter, the benefit of TXA for head injury patients is
slightly attenuated, probably as patients succumbed to non-bleeding-related pathophysiological
mechanisms. This may explain why the effect of early TXA treatment on head injury death is slightly
smaller than the effect of TXA on death due to bleeding seen in the CRASH-2 trial.35
Tranexamic acid did not appear to increase disability among survivors, and there was no evidence of
any increased risk of adverse events. In particular, the risk of DVT, PE, stroke and MI was similar in the
TXA and placebo groups. This is consistent with the results of the CRASH-2 trial35 in traumatic extracranial
bleeding, which also recorded no increased risk of vascular occlusive events with TXA. Unlike the CRASH-2
trial,35 there was no evidence that administration beyond 3 hours of injury increased the risk of head injury
death or any other adverse events. Indeed, given the absence of any adverse effects in this trial, the
implications of wrongly concluding that TXA is ineffective are likely to be far more consequential than
wrongly concluding that TXA is effective.
The CRASH-3 trial provides evidence that TXA is safe in TBI patients and that treatment within 3 hours
of injury reduces head injury deaths.

Strengths and limitations
Our trial had several strengths but also some limitations. The method of randomisation ensured that
participating clinicians had no foreknowledge of the treatment allocation, and the use of placebo
control ensured that outcome assessment was blind to the intervention. Although the eligibility criteria
required the recruiting doctor to be uncertain as to the appropriateness of TXA treatment, because
TXA is not a recommended treatment for isolated TBI, almost all TBIs meeting the inclusion criteria
were recruited. Baseline prognostic factors were well balanced and, because almost all randomly
assigned patients were followed up, there is little potential for bias. The analysis was by intention to
treat (176 patients did not receive any of the trial treatment). The primary outcome was head injury
death as assessed by the responsible clinician. Although some misclassification of cause of death is
inevitable, the assessment was blinded to the trial treatment. All-cause mortality combines causes of

Copyright © 2021 Roberts et al. This work was produced by Roberts et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

33

DISCUSSION

death that might be affected by TXA (e.g. head injury death due to intracranial bleeding) with causes
that we do not expect to be affected by TXA (e.g. sepsis) and, therefore, would be biased towards the
null. Although the CRASH-3 trial is one of the largest trials of TBI, the CIs were wide and compatible
with a substantial reduction in head injury death and little or no benefit. On the other hand, when set
in the context of all the available randomised trials of TXA in TBI, the possibility of no mortality benefit
appears remote.21,22,58 When assessing outcome measures in clinical trials, provided that there are few
false positives (high specificity), estimates of the RR are unbiased even when sensitivity is imperfect.59
For this reason a diagnosis of DVT or PE was recorded only if there was a positive result on imaging
(e.g. ultrasound) or at post-mortem examination. As a result, although the trial may have underestimated
the risk of DVT or PE, the RR estimates for this outcome should be unbiased.
We anticipated that TBI patients with a GCS score of 3 and those with bilateral unreactive pupils prior
to treatment would have little potential to benefit from TXA and that their inclusion in the analysis
would bias the treatment effect towards the null. Most patients with bilateral unreactive pupils already
have extensive intracranial haemorrhage and brain herniation and so it is unlikely that TXA could
improve the outcome in these cases. We therefore prespecified a sensitivity analysis that excluded
these patients. However, patients with unilateral unreactive pupils were not excluded, and because
many of these patients have brain herniation their inclusion might also have diluted the treatment
effect. Indeed, when patients with a GCS score of 3 and those with unilateral or bilateral unreactive
pupils prior to treatment are excluded in a post hoc analysis, the treatment effect is noticeably larger
(RR 0.85, 95% CI 0.74 to 0.96).

Cost-effectiveness
Although the cost of TXA treatment is low, providing treatment will still incur additional costs to the
health service and, therefore, questions arise regarding whether or not this cost represents an efficient
use of resources, based on the benefit associated with treatment. Our analysis shows that TXA is
highly cost-effective in the UK for those with complicated mild and moderate TBI, and is also highly
cost-effective for patients with both pupils reactive. These results were robust across sensitivity
analyses, as probabilistic analyses showed that the intervention is 99% likely to be cost-effective in
both model populations at the NICE willingness-to-pay threshold of £20,000 per QALY. Furthermore,
all deterministic sensitivity analyses produced ICERs below the lower limit of the NICE cost-effectiveness
threshold of £20,000.
The NICE guidelines included TXA for the pre-hospital care of patients with trauma, following the
results of the CRASH-2 trial.60 Our analysis suggests that TXA should also be recommended for
patients with complicated mild and moderate TBI and for patients with both pupils reactive, when
treatment can be provided within 3 hours of injury, as treatment is highly cost-effective.
The cost-effectiveness analysis has some limitations. One limitation is that the trial followed patients for
only 28 days post injury, leading to uncertainty about patient outcomes beyond this time. Furthermore,
evidence on long-term outcomes post TBI in the literature is limited. To capture the long-term additional
risk of death for these patients, we assumed that, after the trial period, the risk of death remained elevated
compared with the risk of death in the general population (four times higher for the first year and two
times higher thereafter). However, these estimates were derived from a case–control study performed in
Scotland, and there is uncertainty as to whether or not the additional risk of death reported in this study
is likely to be reflective of the patients in this trial. Sensitivity analyses were performed to consider the
uncertainty in future outcomes, first, using higher discount rates (giving lower weighting to future events),
and, second, performing a scenario excluding this additional mortality. Both had little impact on the
estimated ICER, with TXA remaining cost-effective in both analyses, suggesting that this uncertainty is
unlikely to affect the overall cost-effectiveness of the treatment.
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In addition, the CRASH-3 trial did not collect direct utility estimates, meaning that they were estimated
from the DRS outcomes at 28 days (or at time of discharge). Although just over half of all mild and
moderate TBI patients had no disability at discharge, there was uncertainty in this estimation process
of overall utility, as well as uncertainty regarding the long-term disability of patients compared with
their status at discharge or 28 days, when some patients’ utility would be expected to improve over
time. To address this, sensitivity analyses with lower utility values, and a lower utility value for those
receiving TXA, were performed. Neither sensitivity analysis influenced the decision on cost-effectiveness.
Last, our analysis was performed from a health service perspective, and therefore did not capture the
potential long-term costs that could be associated with caregiver burden or out-of-pocket medical
payments that might be associated with those living with disability. However, it should be noted that
the disability scores for survivors are similar between groups, and therefore any additional societal
burden associated with TXA treatment would result from a higher proportion of patients surviving
only, as the outcomes among survivors were comparable.
Despite the limitations stated above, we have used robust trial results and supporting evidence from
the literature to show that TXA treatment is highly likely to be cost-effective for the treatment of
patients with complicated mild and moderate TBI and for patients with both pupils reactive, when
provided within 3 hours of injury.

Findings in context
Evidence before this study
Evidence from the CRASH-218 trial that administration of TXA within 3 hours of injury reduces death
in patients with traumatic extracranial bleeding raised the possibility that it might reduce death from
traumatic intracranial bleeding. Intracranial bleeding is common after TBI, and increases head injury
death and disability. Prior to the CRASH-3 trial, we made a systematic search for all randomised trials
of TXA in acute traumatic injury. We searched PubMed, Science Citation Index, National Research
Register, Zetoc, System for Information on Grey Literature in Europe (SIGLE), Global Health, Latin
American and Caribbean Health Sciences Literature (LILACS), Current Controlled Trials, the Cochrane
Injuries Group Specialised Register, CENTRAL, MEDLINE and EMBASE to July 2010. Details of our
search were published previously.61 We found two small randomised trials of TXA in TBI with a total
of 510 patients. Meta-analysis of the two trials showed a statistically significant reduction (RR 0.63,
95% CI 0.40 to 0.99) in death with TXA. However, given the small size of the trials, we considered this
evidence to be hypothesis generating requiring confirmation in larger randomised trials.

Added value of this study
The CRASH-3 trial included 9202 TBI patients who were within 3 hours of injury with either a GCS
score of ≤ 12 or any intracranial bleeding on CT scan and no major extracranial bleeding. The risk of
head injury death was lower with TXA, particularly when patients who had a GCS score of 3 and those
with bilateral unreactive pupils at baseline were excluded as prespecified in the statistical analysis plan
(RR 0.89, 95% CI 0.80 to 1.00). There was no evidence of any increase in disability among survivors.
The risk of vascular occlusive events was similar in both groups.

Implications of all the available evidence
An updated search for randomised trials of the early administration of TXA in patients with TBI
identified one randomised trial in addition to the CRASH-3 trial. This was a randomised trial of
pre-hospital TXA in 967 patients with TBI, which was funded by the US National Institutes of
Health and sponsored by the University of Washington. The dose of TXA was the same as in the
CRASH-3 trial and it also excluded patients with a GCS score of 3 and those with unreactive pupils
at baseline. When the two trials are pooled (Figure 11), there is a reduction in head injury death
with TXA (RR 0.89, 95% CI 0.80 to 0.99) and no evidence of an increased risk in vascular occlusive
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(a)
Study

TXA n/N (%)

Placebo n/N (%)

RR

Perel et al.62

14/133 (10.5)

24/137 (17.5)

0.60 0.33 to 1.11

Yutthakasemsunt et al.21

12/120 (10.0)

18/120 (15.0)

0.67 0.34 to 1.32

Overall

95% CI

0.63 0.40 to 0.99
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(b)
Study

TXA n/N (%)
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RR
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485/3880 (12.5)

525/3757 (14.0)

0.89 0.80 to 1.00

May58

93/603 (15.4)

50/285 (17.5)

0.88 0.64 to 1.20
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0.89 0.80 to 0.99
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FIGURE 11 Summary of (a) previous evidence and (b) current evidence on the effect of TXA on head injury death.

events (RR 0.89, 95% CI 0.71 to 1.13) or seizures (RR 1.08, 95% CI 0.89 to 1.31). When the results of all
available randomised trials are combined there is a reduction in head injury death with TXA (RR 0.88,
95% CI 0.79 to 0.97). Early administration of TXA should be considered in patients with TBI.

Implications for practice in the NHS
Based on the CRASH-218 trial results, TXA was included in guidelines for the pre-hospital care of
trauma patients. Box 1 shows the TXA trauma guideline from the Joint Royal Colleges Ambulance
Liaison Committee (JRCALC).63
BOX 1 The TXA trauma guideline from the Joint Royal Colleges Ambulance Liaison Committee

Treatment of known or suspected severe traumatic internal or external haemorrhage as soon as clinically
possible on arrival at the scene and within 3 hours of bleeding starting in adults and children who are
considered to be at risk of significant haemorrhage. This may be demonstrated by one or more of:
l

l

l

SBP of < 90 mmHg or absent radial pulse or heart rate of > 110 b.p.m. believed to be due to bleeding in
adults. In children this may be demonstrated by changes in the normal physiological parameters for age
(see Joint Royal Colleges Ambulance Liaison Committee page for age).
Any patient where haemostatic gauze, arterial tourniquet(s), chest dressing(s) or pressure dressing(s)
have been applied.
Patient who has suffered a traumatic cardiac arrest.

Contraindications
l
l
l
l
l

Known previous anaphylactic reaction to TXA.
Bleeding started > 3 hours ago.
Obvious resolution of haemorrhage.
Isolated head injury.
Critical interventions required [must be given only after critical interventions have been performed
(i.e. airway managed, control or splinting of major haemorrhage, etc.), and if administration does not
delay transfer, noting that it may be administered en route].

b.p.m., beats per minute.
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As can be seen, patients with isolated TBI are specifically excluded. The CRASH-3 trial provides
evidence that TXA is safe in TBI patients and that treatment within 3 hours of injury reduces head
injury deaths.24 In the light of this evidence, the exclusion of patients with isolated TBI from TXA
treatment guidelines seems unnecessary.
The effect of TXA on head injury-related death appears to depend on the time interval between injury
and the initiation of the trial treatment and on the severity of the TBI. Early treatment of patients with
mild (GCS score of 13–15 and intracranial bleeding on baseline CT scan) and moderate head injury seemed
to confer the greatest mortality benefit. This finding is consistent with the hypothesis that TXA improves
outcomes by reducing intracranial bleeding. Haemorrhage expansion occurs in the hours immediately after
injury and, therefore, treatment delay would reduce the potential for TXA to prevent intracranial bleeding.
Patients with mild or moderate head injury have the most to gain from TXA treatment because, if intracranial
haemorrhage can be prevented, these patients are less likely to die from other life-threatening intracranial
pathologies such as generalised brain swelling, which may not be affected by TXA.
However, the need to rapidly treat the large number of patients who attend emergency departments with
mild or moderate TBI presents challenges for implementation in the NHS. Each year, about 1.4 million
people attend emergency departments in England and Wales with a recent head injury.64 Around 95%
of these patients present with a normal or minimally impaired consciousness level (GCS score of < 12) and
are classified as having mild TBI.64 It is unlikely that all patients attending hospital with mild TBI would be
treated with TXA because the inclusion criteria of the CRASH-3 trial included only those patients with mild
TBI with evidence of intracranial bleeding on their CT scan. Although patients with intracranial bleeding on
their CT scan represent only about 5–10% of patients with mild TBI, this is still a large number of patients.
The indications for TXA treatment in mild TBI are clearly a matter for discussion between clinicians and
policy-makers and will need to take into account considerations of practicality and cost-effectiveness.

Implications for research in the NHS
The CRASH-217 and CRASH-324 clinical trials have shown that i.v. administration of TXA significantly
reduces mortality in trauma patients; however, patients must be treated urgently. Many deaths occur
on the day of the injury and treatment delay reduces the survival benefit from TXA. Immediate TXA
treatment improves survival but the treatment benefit decreases by about 10% for every 15 minutes
of treatment delay until 3 hours, after which there is no benefit.19 To reduce delay, TXA is increasingly
given by paramedics at the scene of injury. Trauma audit data for England and Wales (2016) show that
when TXA is given by paramedics the median time to treatment is 50 minutes, compared with 110 minutes
when TXA is given in hospital.65
One of the main obstacles to further reducing treatment delay is the need for an i.v. injection. Securing
i.v. access at the injury scene can be difficult, particularly for trapped patients. Moreover, on-scene i.v.
cannulation increases pre-hospital times, thus delaying definitive surgical control of bleeding. If TXA could
be given by intramuscular (i.m.) injection, this might reduce the time to TXA treatment and pre-hospital
times. It would also facilitate the more rapid treatment of the large number of patients with mild TBI seen
in UK emergency departments. If, for example, mild TBI patients could be rapidly triaged to identify those
who would benefit from TXA treatment, nursing staff could administer an i.m. injection of TXA while the
patient was waiting to see an emergency physician. Although absorption of TXA from muscle tissue would
involve some delay, the available pharmacokinetic data suggest that an immediate i.m. injection might
achieve therapeutic TXA levels faster than a delayed i.v. injection. As TXA has a wide therapeutic index,
i.m. TXA injection can be followed by an i.v. injection.
The British military also has a strong interest in i.m. TXA use in trauma and is in the early stages of
developing an i.m. TXA auto-injector for combat use.66 An easy-to-use TXA auto-injector would allow
soldiers to administer i.m. TXA to themselves or their colleagues as soon as possible after wounding to
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maximise survival. Such a device could also have implications for civilian trauma, particularly mass
casualty events (the UK incidence is three or four events per year67), as it would facilitate rapid
treatment of a large number of trauma patients. An easy-to-use auto-injector would also raise the
possibility of use by non-medical first aiders.
Studies of i.m. TXA in healthy volunteers show that therapeutic levels (plasma TXA > 10 mg/l) are reached
within 30 minutes of i.m. injection of 500 mg of TXA.68 Administration of 1000 mg (the dose used in
trauma) would achieve therapeutic levels even sooner.69 If absorption was as rapid in trauma patients, this
would strongly suggest the i.m. route as an alternative to i.v. use. The main uncertainty is the impact of
bleeding on muscle absorption of TXA. Acute blood loss leads to compensatory cardiovascular responses
that maintain blood flow to the vital organs at the expense of the peripheral tissues.70 Skin and skeletal
muscle are major targets for these responses, with significant reductions in muscle blood flow. This could
reduce the rate of absorption of TXA from muscle. Studies of i.m. atropine in animal shock models show
that hypovolaemia significantly reduces absorption, although the reductions are modest (10 minutes).71
In most cases, on-scene i.m. injection would be given before shock onset, as only the most severely
bleeding patients have early shock and shock is rare in patients with isolated TBI. Furthermore, because
low-risk patients greatly outnumber high-risk patients, early treatment of low-risk patients prevents more
deaths. To resolve this uncertainty, studies of the pharmacokinetics of i.m. TXA in a spectrum of trauma
patients to assess the time taken to reach therapeutic levels would be a research priority.
To determine whether i.m. TXA has the potential to improve the care of trauma patients, we need to
understand the pharmacokinetics of TXA following i.m. use. If we find that i.m. TXA is well absorbed, with
therapeutic TXA levels achieved in a timely manner, i.m. TXA would provide a rapid alternative to i.v. use
when immediate i.v. administration is not possible. This would expand the treatment options available to
UK paramedics at the scene of a crash and facilitate the development of a TXA auto-injector for use on the
battlefield and during mass casualty events. It would also facilitate early treatment of the large numbers
of patients with mild or moderate TBI seen in UK emergency departments. Because TXA safely reduces
mortality after trauma, this research would provide immediate benefits to patients.
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Chapter 7 Dissemination

A

dissemination plan and a detailed communication strategy were written to guide the dissemination
of the study. These documents expressed the goals of dissemination, identified target audiences and
credible messengers, developed key messages and set out the activities that we planned to undertake.
See Appendix 7 for the dissemination plan.

Audiences
Stakeholder mapping was used to assess the power, influence and interest of each stakeholder.
Neurosurgeons involved in the trial, emergency medicine consultants and paramedics working in
high-income countries emerged as the priority target audiences for the first stage of dissemination
activity. This process helped to hone the communication strategy and ensured that resources were
allocated efficiently to maximise impact.

Messengers
Informal interviews were conducted with medical practitioners in the UK to understand where they
typically access information on medical research and what sources they view as respected and credible.
Interview respondents described the difficulty of keeping up to date with the large volume of new research
being published. Interviewees explained that they increasingly relied on informal, online sources of medical
information rather than on journal articles. One online source highlighted was FOAMed (Free Open Access
Medical education), a collection of open access medical education resources. Contributors to these informal
education resources summarise and appraise important journal articles and present the information in a
variety of formats including blogs, podcasts and videos.

Mediums
Publications and conferences
The trial results were published on an open access basis in The Lancet.24 The results were also
presented at two large international conferences72,73 on the same date to coincide with the publication
of the journal article.

Media
A list of the key online, print and broadcast media outlets based in the UK and the USA was compiled.
Selected journalists were given 5 days’ notice of the press release. The press release was issued to
other media outlets 3 days in advance of the results paper. The press were provided with a media pack
comprising a quote sheet, statistics on the impact of TBI in the UK and globally, and an animation
explaining the trial and study results. Two short films were also produced: one featuring interviews
with the trial chief investigator, a trial neurosurgeon and a trial participant, and the other focusing
solely on the experiences of the trial participant. High-resolution stills from the films were provided.
Furthermore, in order to encourage content production, journalists were offered access to a large
London trauma hospital for filming, interviews with one of the study participants and the trial
investigators, and B-roll footage.

Social media
A social media pack, containing suggested tweets, newsletter copy and Facebook (Facebook, Inc., Menlo
Park, CA, USA) and Instagram (Facebook, Inc., Menlo Park, CA, USA) posts, was shared with trial sites
and charity collaborators. The study funders, which have a large social media following and influence,
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were given advance notice of the results to enable them to plan their social media activity and to sign
off on the branding. FOAMed medical influencers also had advance notice of the results and access to
the trial investigators for questions and interviews.

Out-takes
Press coverage
Online
Between 1 September 2019 and 24 October 2019, CRASH-3 had more than 500 mentions across
online global news sources. The majority of mentions were from UK-based media sites, with just over
10% from US media sources.
Most media sites cross-posted the CRASH-3 team press release or used the resources that we
provided. The British Broadcasting Corporation (BBC) conducted its own interviews, including one with
a study participant.
Although there was a lot of mainstream digital media coverage of CRASH-3, including in The Guardian,
the Independent and the Daily Mail, a number of the articles with broader reach were in science-specific
publications such as Medical News Today, WebMD and BBC Health.
Unexpectedly, a number of regional papers also featured the story. Although they have a lower reach
individually, cumulatively this resulted in broad coverage.

Broadcast media
There were 86 broadcast pieces featuring CRASH-3 between 1 September and 24 October 2019.
The majority were covered by the BBC as well as various radio stations in the USA, the Pakistani news
channel City 42 Pakistan and the Kurdish news channel Rudaw.

Social media
Between 1 October 2019 and 31 October 2019, there were over 2000 mentions of CRASH-3 on
Twitter (Twitter, Inc., San Francisco, CA, USA). Over one-quarter of the mentions originated from UK
sources (28%), followed by the USA (12%) and Canada (10%).
Twitter activity from The Lancet and the Department for International Development achieved the
highest reach. The Wellcome Trust, the National Institute for Health Research and the MRC, which
funded the study, also featured in the top 10 posters by reach. FOAMed channels were particularly
successful in achieving a large and targeted reach. The Resus Room podcast, which is a FOAMed site,
had > 16,000 downloads of their podcast on CRASH-3.

What worked well
Advance notice of results
Certain media contacts, including the BBC, the study funders and FOAMed medical influencers, were
given advance notice of the trial results. This allowed them to plan media and social media content and
share the results on our behalf:
CRASH 3 has been our most popular episode ever (approximately 10% greater than previous, which is a
jump from what we expect) . . . From experience, advertising the paper prior to publication in the way that
was done makes a large impact on its reach and it is something that we plan to continue with future
papers that we will be covering.
Reproduced with permission from Simon Laing, The Resus Room, 2021, personal communication
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Know your audience
Interviews with medical professionals during the development of the communication strategies
identified FOAMed as a credible information source for our key audiences. Owing to their large social
media following, FOAMed contributors proved to be our most successful targeted route for dissemination.
As well as access to the results paper prior to the publication of the article, medical influencers were also
given complete creative and intellectual freedom on the interpretation of the results.

Flexible content
A variety of resources were developed, including short videos, photographs, infographics and animations,
allowing content to be shared through different channels. Permission was also given to adapt the resources,
making it much easier for busy communications teams to work with and share our material. UK Aid Direct
(© 2019 UK Aid Direct) made a branded version of one of the videos that we produced to tie in with an
ongoing campaign that it was running. In addition, by offering a filming site and interviews with a study
participant and trial investigators, we supported others to develop their own content.

What we learned
Choose content carefully
An animation explaining the trial results was created to support the dissemination of the study; however,
the animation was costly to produce and generated little engagement. The infographics, on the other hand,
were inexpensive to make and were shared widely. Owing to the long lead time required for producing an
animation, it was commissioned prior to knowledge of the trial results. Consequently, the messaging was
not as strong as we would have liked. It is possible that a high-tech video explaining the mechanism of
action of TXA would have been a more successful angle.

Consider patient case studies for dissemination as part of trial design
The BBC interviewed one of the study participants as part of its coverage of the trial. This provided
the human interest element to the story and was well received. Studies should consider cultivating a
case study portfolio of trial participants who would be interested in speaking about their experiences.
This could be achieved by giving study participants the option, in the participant information sheet,
to opt in to communications from the trial team.

Make the most of collaborators
Most hospitals have communications teams that are keen to share information relating to research in
which they have been involved. Support from communications teams to share trial results on social
media can be helpful to target messages to relevant local and regional hospital staff and decision-makers.

Debate can be good
There was a lack of consensus among FOAMed contributors on the conclusions that were drawn from
the results of the trial. This, in turn, generated further discussion, debate and social media activity.
The CRASH-3 team did not directly engage in these debates, but several of our trial collaborators
who are active on social media responded to the comments and questions tweeted. Individuals who
are respected in their field, active on Twitter and defenders of your work, can become your social
media champions.

Think outside the box
Although it is important to utilise existing tried-and-tested dissemination approaches, this field benefits
from a willingness to innovate, take risks and try new things. Gamifcation is an area of growing interest
in medical education. One idea we are exploring is designing a mobile app-based (application-based)
game aimed at medical practitioners to explain the mechanism of action of TXA.
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Chapter 8 Reflections and concluding
remarks

T

he CRASH-3 trial found that a low-cost, widely available drug reduces death after TBI by up to
20%, depending on the severity of injury.24 The CRASH-3 trial is the largest clinical trial in TBI and
the first to identify a safe and effective neuroprotective drug. If widely implemented, TXA could prevent
over 100,000 deaths each year worldwide. The CRASH-3 trial builds on the success of the CRASH-2
trial,17 which showed that TXA reduces deaths in traumatic extracranial bleeding. Based on the CRASH-2
trial results, TXA was included on the WHO Model List of Essential Medicines74 and incorporated into
trauma treatment guidelines worldwide. The CRASH-2 trial was considered by RAND Europe as
providing an excellent return on the research investement.75
Obtaining funding support for the CRASH-3 trial was not straightforward, with applications to the MRC
and HTA initially rejected. Commissioners’ concerns, which in the authors’ opinion were unfounded,
included the potential for bias in a study with many hospitals; the challenge of obtaining participant
consent; value for money of initial proposals; and complexity of managing international trials. The
authors believe that proper randomisation, placebo control, complete follow-up and objective outcomes
(e.g. death) avoid bias and that unconscious patients with life-threatening emergencies are an exception
to the general rule of patient informed consent. As regards value for money, the authors believe that
providing reliable and definitive answers in a large adequately powered trial provides much better value
for money than by conducting many smaller trials over a longer period. Fortunately, the successful
international pilot phase involving over 1000 patients, funded by the JP Moulton Charitable Trust,
demonstrated the feasibility of the CRASH-3 approach. The CRASH-218 and CRASH-3 trials show that
early treatment with TXA safely reduces mortality in low-, middle- and high-income countries. There is no
evidence that the effects of TXA vary by a country’s income level. NHS patients were the first to benefit from
the results of these global trials. Even sooner than this, the British Army incorporated TXA into combat care
treatment protocols, resulting in a demonstrable reduction in combat deaths.76 The authors believe that it is
more efficient to conduct adequately powered international trials that provide reliable answers for patients
everywhere than to conduct smaller or less efficient trials within the borders of the UK.
Although recruitment was rapid, we extended the trial for scientific reasons. New research had suggested
that the recruitment window of 8 hours was too long and that it should be shortened to 3 hours.
The protocol was amended accordingly. This substantially reduced recruitment; however, UK research
nurses and international collaborators worked hard to ensure that few eligible patients were missed and
that patients were randomised and treated urgently. Although UK research nurses were critical to the
success of the trial, many hospitals have no research nurse cover at night and weekends, periods when
trauma is most common, and this resulted in reduced recruitment.
Trials have become more expensive. The CRASH-218 trial (20,210 patients) cost approximately £2M;
however, 10 years later, the CRASH-3 trial (12,737 patients) cost approximately twice this amount.
One reason for this increase in cost is burgeoning clinical trial bureaucracy. To conduct a multinational
trial, approval must be obtained from the competent authority and National Ethics Committee of each
participating country. In the European Union (EU), the Clinical Trials Directive was introduced to
simplify and harmonise the administrative processes around clinical trials.77 The Directive stated that
each Member State should:
1. require a standard list of documents for review of a trial
2. accept the English language in their communications with applicants and for documentation that is
not aimed at the public or the trial participant
3. provide an opinion on the trial within a maximum of 60 days.
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Hospitals from 15 EU countries expressed an interest in taking part in the CRASH-3 trial. Seven of these
countries required documents that are not part of the EU Directive standard list. Six countries required
the full application form in their local language (i.e. Croatia, France, Greece, Italy, Lithuania and Portugal)
and seven countries required the Investigational Medicinal Product labelling in their local language
(i.e. Belgium, the Czechia, Greece, Hungary, Latvia, Lithuania and Portugal). Of the seven countries where
competent authority approval was obtained, Belgium and the UK were the only two that complied with
the 60-day timeline. For the other five countries (i.e. Ireland, Italy, Romania, Slovenia and Spain), the
review time ranged between 64 and 291 days.
Of the six countries in which national ethics committee review approval was obtained, only two complied
with the 60-day review timeline (i.e. Spain and the UK). In the other countries (i.e. Ireland, Italy, Romania
and Slovenia), the review times ranged between 114 and 293 days. The cost of ethical review varied
widely, with the Czechia charging £1162 for up to 10 sites and £116 for each additional site. There was
no charge in the UK.
The sponsor global insurance policy (a worldwide policy excluding the USA) did not meet with the
requirements of some EU countries, including Belgium, Germany and Italy. As there was no budget for
additional insurance, we could not run the trial in Germany. In Italy, the investigators institutional
ethics committee (Comitato Etico della Provincia di Brescia) found and paid for insurance. In Belgium,
the investigators’ institutional ethics committee (Ethisch Comite UZ Gent) suggested that we delegate
the responsibility for insurance to it. These responses were commendable and show the commitment
to patient-relevant research.
With the implementation of the EU Clinical Trials Directive, it was anticipated that the approvals
process throughout the EU would be streamlined and standardised. However, the additional costs for
translation and review, and delays in obtaining approvals added to the costs of the trial.
We are grateful to the UK taxpayer for the opportunity to conduct this trial. We believe that the
results will improve the care of patients with TBI in the UK and worldwide and we sincerely hope that,
like the CRASH-218 trial, the CRASH-3 trial will be seen as providing a good return on the research
investment. The trial team will continue to work with policy-makers to ensure that patients benefit.
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Appendix 1 CRASH-3 trial organisation
Trial Steering Committee
Peter Sandercock (Chairperson), Henry Benjamin Hartzenberg, Manjul Joshipura (2011–16),
Amy Aeron-Thomas (Patient Representative), Ian Roberts, Pablo Perel and Haleema Shakur-Still.

Data Monitoring Committee
Michael J Clarke (Chairperson), Samuel C Ohaegbulam, Anthony Rodgers and Tony Brady
(Independent Statistician).

Trial Co-ordinating Centre Team
Nigeria co-ordinating team: Bukola Fawole (Co-ordinating Centre Director), Olusade Adetayo
(Assistant Trial Co-ordinator), Olujide Okunade (Assistant Trial Co-ordinator) and Temitayo Shokunbi
(Clinical Lead).
Pakistan co-ordinating team: Rizwana Chaudhri (Co-ordinating Centre Director), Kiran Javaid (Assistant
Research Co-ordinator), Rashid Jooma (Clinical Lead) and Aasia Kayani (Research Co-ordinator).
National Co-ordinators: Rizwana Chaudhri (Pakistan), Rashid Jooma (Pakistan), Sabariah Faizah Bt
Jamaluddin (Malaysia), Julina Md Noor (National Co-ordinator’s Assistant, Malaysia), Tamar Gogichaishvili
(Georgia), Maria de los Angeles Munoz-Sanchez (Spain), Bukola Fawole (Nigeria), Temitayo Shokunbi
(Nigeria), Jorge Mejia-Mantilla (Colombia), Liliana Vallecilla (Colombia), Fatos Olldashi (Albania),
Satish Krishnan (United Arab Emirates), Vincent Djientcheu (Cameroon), Jorge Loria Castellanos (Mexico),
Frank Rasulo (Italy), Qadamkhear Hama (Iraq), Yakub Mulla (Zambia), Ioan Stefan Florian (Romania),
Juan Tobar (El Salvador), Hussein Khamis (Egypt), Conor Deasy (Ireland), Bobby Wellsh (Papua New Guinea),
Jean Williams-Johnson (Jamaica), Susilo Chandra (Indonesia) and Vincent Mutiso (Kenya).

CRASH-3 trial collaborators by country
The number of participants recruited is shown in brackets.
Pakistan (4567). Lahore General Hospital Neurosurgery Unit I (1178): Rizwan Butt,
Muhammad Hammad Nasir, Salman Ahmad, Farwah Aslam, Khurram Ishaque, Faheem Usmani,
Shahrukh Rizvi, Farhad Ali, Omair Sajjad and Ali Zunair. Jinnah Postgraduate Medical Centre (700):
Lal Rehman, Raza Rizvi, Farrukh Javeed, Shakeel Ahmed, Asad Abbas, Ali Afzal and Ali Mikdad.
Lahore General Hospital Neurosurgery Unit III (648): Asif Bashir, Anwar Chaudary, Tariq Salahuddin,
Bashir Ahemed, Shahrukh Rizvi, Faheem Usmani and Amir Aziz. Jinnah Hospital Lahore (619):
Naveed Ashraf, Shahzad Hussain, Usman Ahmad, Muhammad Asif, Muhammad Adil and Adeel Rauf.
Lahore General Hospital Neurosurgery Unit II (607): Khalid Mahmood, Rizwan Khan, Bilal Ahmad,
Umair Afzal, Hassan Raza and Quratul Ain. District Headquarters Hospital Narowal (303): Sajjad Yaqoob,
Qaiser Waseem, Muffasser Nishat, Suneel Semvel and Javed Iqbal. Services Hospital Lahore (226):
Samra Majeed, Sana Zulfiqar, Madeeha Iqbal, Nazia Majeed and Manzoor Ahmed. District Headquarters
Rawalpindi (137): Nadeem Akhtar, Mohammad Malik, Yasir Shehzad and Muhammad Yousaf.
District Headquarters Hospital Khuzdar (65): Abdul Wahid, Abdul Samad and Saifullah Shah.
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Lady Reading Hospital (31): Mumtaz Ali and Jehan Zeb. Shifa International Hospital (29): Abdus Salam
Khan and Adeela Irfan. Liaquat National Hospital and Medical College (14): Salman Sharif. Liaquat
University Hospital (7): Riaz Memon. Aga Khan University Hospital (3): Rashid Jooma.
UK (3143). Royal London Hospital (501): Ben Bloom, Tim Harris, Jason Pott, Imogen Skene,
Geoffrey Bellhouse and Olivia Boulton. University Hospital Coventry (312): Caroline Leech,
Geraldine Ward, Catherine Jarvis, Carly Swann and Sathananathan Ratnam. Queen Elizabeth Hospital
Birmingham (302): Antonio Belli, Ronald Carrera, Kamal Yakoub, David Davies and Emma Fellows.
St George’s Hospital (280): Phil Moss, Heather Jarman, Sarah Rounding, Elizabeth Johnson and
Catherine Loughran. Salford Royal Hospital (176): Fiona Lecky, Kate Clayton, Angiy Michael and
Angela Coumbarides. Southmead Hospital (156): Jason Kendall, Beverley Faulkner, Ruth Worner
and Emma Gendall. King’s College Hospital (155): Philip Hopkins, Paul Riozzi, Hannah Cotton and
Raine Astin-Chamberlain. St Mary’s Hospital, London (117): Mark Wilson, Jan Bodnar, Rachel Williams
and Alberto Rigoni. Aintree University Hospital (108): Abdo Sattout, John Fletcher, Calum Edge
and Nina Maryanji. Addenbrooke’s Hospital (103): Adrian Boyle, Susie Hardwick, Ellen Nichols and
Catherine Hayhurst. Queen’s Medical Centre (100): Frank Coffey, Chris Gough, Philip Miller and
Lucy Ryan. John Radcliffe Hospital (76): Melanie Darwent, Alexis Espinosa and Sally Beer. Royal Stoke
University Hospital (71): Julie Norton, Holly Maguire and Kay Finney. Derriford Hospital (67):
Anthony Kehoe, Rosalyn Squire and Alison Jeffery. Queen Alexandra Hospital (60): Christiane Vorwerk,
Denise Foord and Eliot Wilkinson. Northern General Hospital (57): Avril Kuhrt, Shammi Ramlakhan and
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Appendix 2 Consent procedure overview
Patient unable to consent
Patients in this trial are unable to consent for themselves due to impairment
in their mental capacity caused by traumatic brain injury

Relative (if available) is given brief information – not expected to
provide valid informed written consent, only agreement
If available, this sudden acute traumatic situation will have immense emotional and
psychological effects on relatives – consider their ability for informed decision-making
Treatment for their relative is required urgently. The nature of the trial also requires
urgent action. It is not reasonable to expect relatives to provide valid, informed written
consent in the critical emergency situation. They may be able to agree or disagree

Agreement given by relative or no relative present
Two clinical personnel, one independent of the trial, decide to enrol the
patient into the trial?

Yes

No

Randomise patient

Do not randomise

As soon as possible after the
emergency is over or patient
regains competence, give full
information and seek written
consent from relative or patient
for continuation in the trial
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Appendix 3 Total randomisations by
geographical region
TABLE 17 Randomisations by geographical region and treatment group
Geographical region
Africa

TXA (n)

Placebo (n)

Total (N)

301

289

590

Asia

3905

3860

7765

Europe, Australia and North America

2009

1993

4002

186

184

370

5

5

10

6406

6331

12,737

Caribbean, Central and South America
Oceania
Total
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Appendix 4 Cumulative incidence of head
injury death by treatment group in patients
randomised within 3 hours of injury

F

Cumulative % of head injury deaths

igure 12 shows the cumulative incidence of head injury death in the TXA and placebo groups by
days since randomisation in all patients randomised within 3 hours of injury. The numbers at risk at
time points 0, 7, 14, 21 and 28 days after randomisation are presented in the risk table.

20

15
Log-rank p-value = 0.121
TXA
Placebo

10

5

0
0

7

14

21

28

Time since randomisation (days)
Number at risk
TXA
Placebo

4613
4514

3868
3744

3738
3618

3694
3579

3683
3566

FIGURE 12 Cumulative incidence plot of the prespecified primary outcome.
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Appendix 5 Adverse events by treatment
group in all patients
TABLE 18 Adverse events by treatment group in all patients
Adverse event

TXA (n = 6359)

Placebo (n = 6280)

Total (n = 12,639)

Any adverse event

198

168

366

Pneumonia

51

50

101

Respiratory infection

10

7

17

Fall

11

5

16

Urinary tract infection

9

5

14

Abnormal liver function tests

6

6

12

Allergic reaction

4

5

9

Cellulitis

4

4

8

Wound infection

4

3

7

Atrial fibrillation

5

1

6

Headache

5

1

6

Pneumothorax

4

2

6

Supraventricular tachycardia

3

2

5

Cerebral haemorrhage

1

3

4

Ileus

1

3

4

Pyrexia

2

2

4

Urinary retention

3

1

4

Cardiac arrest

3

0

3

Chest pain

3

0

3

Constipation

1

2

3

Haemothorax

1

2

3

Heart block

1

2

3

Infection – MRSA

1

2

3

Intracranial venous sinus thrombosis

1

2

3

Meningitis

1

2

3

PE

3

0

3

Respiratory failure

0

3

3

Acute respiratory distress syndrome

1

1

2

Anaemia

0

2

2

Atrial flutter

1

1

2

Cerebral haematoma

2

0

2

Clostridium difficile infection

2

0

2
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TABLE 18 Adverse events by treatment group in all patients (continued )
Adverse event

TXA (n = 6359)

Placebo (n = 6280)

Total (n = 12,639)

Diarrhoea

2

0

2

Epilepsy

0

2

2

Gangrene

2

0

2

Hypertension

0

2

2

Hypokalaemia

1

1

2

Intestinal pseudo-obstruction

1

1

2

Ischaemic stroke

2

0

2

Neutropenia

2

0

2

Pancreatitis

1

1

2

Rash

1

1

2

Respiratory arrest

1

1

2

Seizure

1

1

2

Sepsis

1

1

2

Thrombocytopenia

2

0

2

Thrombocytosis

1

1

2

TBI

1

1

2

Unintended unilateral bronchial intubation

1

1

2

Wound dehiscence

0

2

2

Abdominal compartment syndrome

1

0

1

Abdominal distension

0

1

1

Acute alcoholic intoxication

1

0

1

Agitation

1

0

1

Atelectasis

0

1

1

Bacteraemia

0

1

1

Bowel obstruction

1

0

1

Bradycardia

0

1

1

Central line infection

1

0

1

Cerebral salt-wasting syndrome

1

0

1

Cerebrospinal fluid leakage

0

1

1

Cerebrospinal infection

1

0

1

Cervical pain

0

1

1

Corneal ulcer

1

0

1

Cranial nerve palsies multiple

0

1

1

Cranial nerve paralysis

1

0

1

Depression

1

0

1

Diabetic ketoacidosis

1

0

1

Electrocardiographic signs of myocardial ischaemia

0

1

1

Eye injury

1

0

1
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TABLE 18 Adverse events by treatment group in all patients (continued )
Adverse event

TXA (n = 6359)

Placebo (n = 6280)

Total (n = 12,639)

Facial palsy

0

1

1

Foot drop

0

1

1

Fractured zygomatic arch reduction

0

1

1

Haematoma

1

0

1

Haematuria

0

1

1

Haemophilus influenza pneumonia

0

1

1

Herpes zoster infection

1

0

1

Hip dislocation

0

1

1

Humerus fracture

1

0

1

Hydrocephalus

0

1

1

Hyperbilirubinaemia

1

0

1

Hypernatraemia

1

0

1

Hyponatraemia

1

0

1

Hypotension

1

0

1

Hypothermia

0

1

1

Jaw pain

1

0

1

Laceration of head

1

0

1

Laryngopharyngitis

1

0

1

Leg pain

0

1

1

Liver failure

0

1

1

Metabolic encephalopathy

1

0

1

Necrotising fasciitis

0

1

1

Neuroleptic malignant syndrome

0

1

1

Obstructive jaundice

0

1

1

Overdose

0

1

1

Painful urination

0

1

1

Paraesthesia

1

0

1

Pleural effusion

0

1

1

Post-procedural infection

0

1

1

Psychotic episode

1

0

1

Pulmonary haemorrhage

1

0

1

Pulmonary oedema

0

1

1

Rectal bleeding

1

0

1

Shunt infection

1

0

1

Sinus pause

1

0

1

Stroke

1

0

1

Thrombocythaemia

0

1

1
continued
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TABLE 18 Adverse events by treatment group in all patients (continued )
Adverse event

TXA (n = 6359)

Placebo (n = 6280)

Total (n = 12,639)

Thyroid haemorrhage

1

0

1

Toothache

0

1

1

Tracheostomy

0

1

1

Tracheostomy complication

0

1

1

Tracheostomy infection

1

0

1

Vasovagal reaction

0

1

1

Ventricular fibrillation

0

1

1

Ventricular tachycardia

0

1

1

Ventriculitis

1

0

1

Vocal cord paresis

1

0

1

MRSA, meticillin-resistant Staphylococcus aureus.
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Appendix 6 Cost-effectiveness analysis
Disability Rating Scale outcomes
The DRS outcomes, stratified by population, are presented in Table 19. In order to estimate the utility
and monitoring costs post TBI, we estimated the GOS score corresponding to each level of disability,
as reported for the DRS score. We also utilised clinical feedback for this estimation process.

Utility estimation: correlation between Glasgow Coma Scale score and
Glasgow Outcome Scale from previous randomised controlled trial (scenario)
An alternative estimation process was considered, to predict the utility in each population. A previous
analysis showed the distribution of GOS outcomes (good recovery, moderate disability, severe
disability) stratified by GCS score.46,78
For a sensitivity analysis, we used the GCS scores from the CRASH-3 patients to estimate a
distribution of GOS scores, to which the utility values estimated by Ward Fuller et al.45 (see Table 9)
were applied.

Long-term model survival predictions
The survival of patients by treatment group is shown for the first 3 months of the model (Figure 13)
and for the duration of the model time horizon (Figure 14).

TABLE 19 Estimating disability severity from DRS to estimate health state utility

DRS score

Level of disability (based on
DRS score)28

Mild/moderate (n)

Both pupils
react (n)

Estimated corresponding
GOS outcome

0

None

2845

3172

Good recovery

1

Mild

249

306

2–3

Partial

775

907

4–6

Moderate

513

638

7–11

Moderately severe

384

539

12–16

Severe

157

245

17–21

Extremely severe

136

300

22–24

Vegetative state

78

205

25–29

Extreme vegetative state

46

154

5183

6466

Total

Moderate disability

Severe disability

Vegetative state
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TABLE 20 Distribution of GOS outcomes, by GCS scores at injury, derived from previous CRASH trial46,78
GOS outcome among survivors
GCS score at injury

Good recovery (%)

Moderate disability (%)

Severe disability (%)

3

28.9

30.8

40.3

4

20.6

25.8

53.6

5

22.9

30.6

46.5

6

33.4

34.0

32.6

7

44.0

29.9

26.1

8

45.9

32.7

21.4

9

56.8

26.0

17.2

10

57.7

27.1

15.2

11

65.2

22.7

12.0

12

68.5

19.7

11.8

13

75.2

16.2

8.6

74.5

16.6

9.0

74.5

16.6

9.0

14
15

a

a GCS score of 15 assumed equal distribution of severity to GCS score of 14 in the absence of data.

TABLE 21 Distribution of GOS outcomes and estimated utility for CRASH-3 patients, for patients in each model
population
GOS outcome among survivors
CRASH-3 population

Good recovery (%)

Moderate disability (%)

Severe disability (%)

Estimated utilitya

Mild or moderate TBI

59.4

23.2

17.4

0.79

Both pupils reactive

68.5

20.1

11.4

0.76

a Utility estimated by weighted average of GOS scores, based on utility estimates reported in Table 9.
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0.95
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0.80
0

1
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FIGURE 13 Model predictions for survival for 3 months by treatment group. Vertical dotted line represents 28-day
trial period.
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FIGURE 14 Model predictions for survival for the duration of the analysis time horizon by treatment group.
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Appendix 7 Dissemination plan

Tranexamic acid for the treatment of traumac
brain injury: an internaonal randomised trial
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Disseminaon strategy

1. Background
Each year, world-wide, about 27 million people (95% CI 24 - 30 million) will experience a
traumac brain injury (TBI). About 2 million people will die but many millions will live with a
TBI related disability. Road traﬃc crashes and falls are the leading causes. TBI is a major public
health problem everywhere regardless of country income or level of development. Although
the risk of TBI seem to be greatest in high income countries, this may be an artefact due to
the lack of reliable data from low and middle income countries. Nevertheless, the number of
cases of TBI is greatest in low and middle income countries because they have a much larger
populaon. The incidence of TBI increases with age. With increasing use of motor vehicles
and populaon ageing, the global incidence of TBI is expected to increase.
2. The CRASH-3 trial
The CRASH-3 trial is an internaonal, multi-centre, randomised trial of the eﬀects of early
administraon (within 3 hours of injury) of tranexamic acid on death and disability in TBI
paents. Adults with TBI within 3 hours of injury, with any intracranial bleeding on CT scan or
who have a GCS of 12 or less, and no signiﬁcant extra cranial bleeding are eligible. We hope
that tranexamic acid will reduce death and disability after TBI by reducing the extent of
bleeding into the brain or into the skull which may cause death or disability by exerng
pressure on the brain.
The me window for eligibility was originally within 8 hours of injury but in 2016 we changed
the protocol to limit recruitment to paents who are within 3 hours of injury. This was done
in response to accumulang evidence that the TXA treatment is unlikely to be eﬀecve when
given beyond 3 hours of injury and might even do more harm than good. We recruited nearly
13,000 paents from hospitals world-wide. The primary outcome is head injury death in
hospital within 28 days of injury in paents treated within 3 hours of injury but we will also
asses and report on levels of disability.
3. Objecves of disseminaon
3.1 Make the results clear and explain the biological mechanisms
The ﬁrst objecve is to make the result clear. TXA is a drug that reduces bleeding by inhibing
ﬁbrin clot breakdown, a process called ﬁbrinolysis. Most head injury paents are managed by
neurosurgeons who have only a rudimentary understanding of haematology. One of the main
obstacles to implemenng the results of the CRASH-2 trial of TXA in extra-cranial bleeding
was that emergency physicians knew very lile about ﬁbrinolysis. Indeed, shortly after
publication of the CRASH-2 trial results, an US doctor posted a highly viewed video explaining
the trial results.
hps://www.youtube.com/watch?v=YXPU_MEd5vg
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Whilst reasonably accurate, it could have been beer and we should have done this. The
general level of haematology understanding should be higher now as a result of the CRASH-2
trial, but we must not overestimate neurosurgeons knowledge about ﬁbrinolysis and need to
prepare media that explain the results. We must also bear in mind that doctors understanding
of epidemiology and biostastics is extremely limited and that pathophysiological explanaon
is much more important. You may have a highly stascally signiﬁcant beneﬁt from a large
randomised trial but the results will not be implemented unless doctors understand the
mechanism of acon. Biological mechanism is narrave and narrave is the only thing that is
memorable.
3.2 Make sure that we have everything that journalists need for publication day.
We need paent stories about the impact of TBI on the lives of paents and their families.
Ideally, we would have this for high (UK) and middle income countries (e.g. Pakistan). We
don’t know what the results show yet but we are reasonably sure that any treatment eﬀect
will be me dependent in that earlier treatment will be most eﬀective and late treatment
least eﬀecve. Our ﬁlm footage should therefore emphasise me to treatment and the need
for urgency. We need to idenfy paents who are willing and able to talk about the results to
the media on the day of publication. We need to idenfy some authoritave independent
experts (possibly including WHO) willing to discuss the trial results in the media. We should
liaise with the funders (NIHR, MRC, DFID, Wellcome) to make sure they know the results are
coming and to link in with their press oﬃces.
3.3 Make sure that we meet the publicaon deadline.
We have been invited to present the trial results at two large international meengs that are
happening at the same me: The World Congress on Intensive Care
(hps://www.worldcongressintensivecare2019.com/) in Melbourne which IR will aend and
the Neuro-crical Care Society Annual Meeng in Vancouver which HS will aend
(hps://www.neurocricalcare.org/events/annualmeeng). Ideally, we would me the
publication of the trial results to coincide with these presentaons. The meengs would be a
good disseminaon opportunity.
3.4 Engage with stakeholders in advance of the results being published
Although the burden of death and disability from TBI is far greater than for PPH, there is much
less global coordinaon of treatment policy decision making and far fewer “authoritave”
bodies. Nevertheless, we should engage with key stakeholders and leaders (including paent
organisaons of which Headway is the most important in the UK). We need to build a
database of key stakeholders as we did for the Woman trial and let them know about the trial
well in advance of publicaon and the trial results just before publicaon.
3.5 Help our collaborators to disseminate the results in their respecve countries.
Develop disseminaon tools that collaborators can use for naonal and internaonal
audiences. We need to upgrade our trial website and make sure that it hosts all of the trial
disseminaon materials that can be downloaded and used locally. We need to help naonal
co-ordinators to achieve press coverage in their respecve countries. Unlike the Woman trial
there will be no focus countries since TBI is a major public health issue in every country of the
world. However, we will focus our eﬀorts where we have good contacts. Making an impact in
the UK will be important since this inﬂuences treatment decisions in other countries.
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Specific outputs:
1. Short videos that explain the trial procedure and the results in pathophysiological
terms
2. Authoritave explanaon of the results from respected neurosurgeons that have
contributed importantly to the trial (e.g. Prof Rashid Jooma in Pakistan and Prof Tony
Belli in the UK). Membership of the trial steering commiee is shown below.
3. One page infographic that summarises the trial and the results that can be
disseminated similar to the one prepared for the woman trial.
4. Film footage of vicm experiences from UK and Pakistan
5. Film footage that emphasise urgency and the importance of reducing treatment delay
6. Idenfy vicms of TBI who are prepared to talk to the media (consider approaching
Headway and RoadPeace for this). hps://www.headway.org.uk/
7. Idenfy independent experts who are prepared to talk to the media
8. Co-ordinate the dates of the publicaon to the world congresses.
9. Build a database of key stakeholders and provide advance warning of the results.
10. Upgrade the trial website – make sure that it hosts trial related materials that can be
downloaded by invesgators and others and used for disseminaon.
11. Photography – we need high resoluon sll photos from the ﬁlm
12. Social media toolkit to share with partners and stakeholders so that everyone has
content and messaging to share via their channels
13. Media plan and materials – speciﬁcs will depend on results, but may include a press
release(s) for examples, and media pitches for speciﬁc outlets, plus case studies.
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